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ABSTRACT 
Aggressive behaviours of solid tumours are influenced by the tumour microenvironment. Multiple 
signalling pathways can influence the behaviour of stromal fibroblasts in tumours, but how these 
events are coordinated to generate tumour-promoting cancer-associated fibroblasts (CAFs) is not 
well understood. Here we show that stromal expression of Dickkopf-3 (DKK3) is associated with 
aggressive breast, colorectal and ovarian cancers. We demonstrate that DKK3 is a HSF1 effector 
that modulates the pro-tumorigenic behaviour of CAFs in vitro and in vivo. DKK3 orchestrates a 
concomitant activation of β-catenin and YAP/TAZ. Whereas β-catenin is dispensable for CAF-
mediated ECM remodelling, cancer cell growth and invasion, DKK3-driven YAP/TAZ activation is 
required to induce tumour-promoting phenotypes. Mechanistically, DKK3 in CAFs acts via 
canonical Wnt signalling by interfering with the negative regulator Kremen and increasing cell-
surface levels of LRP6. This work reveals an unpredicted link between HSF1, Wnt signalling and 
YAP/TAZ relevant for the generation of tumour-promoting CAFs. 
INTRODUCTION 
Stepwise acquisition of genetic alterations is crucial for the initiation of primary epithelial tumours. 
Yet, increasing evidence supports the notion that concomitant stromal changes play a critical role in 
cancer progression in many types of neoplasias 1, 2. Fibroblasts constitute a significant proportion of 
the stromal compartment in many solid tumours. As opposed to normal fibroblasts, which are 
generally anti-tumorigenic 3, cancer-associated fibroblasts (CAFs) present a pathological activated 
phenotype that enables them to influence tumour progression, dissemination and response to 
therapy through remodelling of the extracellular matrix and signalling to cancer, endothelial and 
immune cells 4, 5. In CAFs, signalling pathways such as Heat-Shock Factor 1 (HSF1) and YAP/TAZ are 
activated in response to cellular stress and mechanical cues, respectively6, 7. In turn, HSF1 affects 
signalling to cancer cells promoting tumour growth whereas YAP promotes cancer cell invasion and 
angiogenesis through remodelling of the extracellular matrix (ECM). Thus, each pathway is regulated 
by different mechanisms and controls a defined set of functions; whether these molecular events 
are interconnected to regulate the emergence of a fully activated CAF phenotype is not known.  
Dickkopf (DKK) proteins comprise a conserved family of secreted negative regulators of β-catenin 8. 
DKK1, DKK2, and DKK4 have been shown to antagonize Wnt-mediated β-catenin stabilization by 
binding and down-modulating Wnt co-receptor LRP5/6 9, 10. In contrast, DKK3 does not interact with 
LRP5/6 and thus is not considered a true Wnt signalling antagonist. The role of DKK proteins in 
cancer is thought to be mainly tumour suppressive, as they are commonly downregulated in cancer 
cells and can negatively affect proliferation and survival. Yet, the role of DKK proteins in cancer 
stroma is still understudied.  
In this study we uncover an unprecedented role for DKK3 in linking HSF1 and YAP/TAZ signalling. We 
demonstrate that DKK3 is a HSF1 target gene that promotes aggressive behaviours in CAFs by 
potentiating YAP/TAZ activity via canonical Wnt signalling. Mechanistically, we show that DKK3 
promotes LRP5/6 activity by interfering with the negative Wnt regulator Kremen1/2. 
RESULTS 
DKK3 expression levels in the tumour microenvironment 
The initial evidence suggesting that DKK3 may play a role in the regulation of the tumour 
microenvironment came from analyses of stromal gene expression in normal and cancerous tissues 
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(Supplementary Figure 1a). DKK3 gene and protein expression is significantly upregulated in the 
tumour stroma in several types of cancers including breast, colon and ovarian (Supplementary 
Figure 1a and Figure 1a-c). DKK3 is part of the Dickkopf family of secreted negative regulators of β-
catenin8. Dickkopf proteins mainly act as tumour suppressors, as they are commonly downregulated 
in cancer cells and inhibit proliferation and survival11. The role of Dickkopf proteins in cancer stroma 
has not been established. Stromal expression of other Dickkopf genes across various cancer types 
was less consistent (Supplementary Figure 1a), suggesting that DKK3 is the only Dickkopf factor 
commonly associated with cancer stroma. DKK3 protein levels in breast cancer (BC) stroma were 
significantly increased upon progression to more aggressive cancers, particularly in ER-negative BC 
(Figure 1d and Supplementary Figure 1b). Furthermore, in ER-negative BC there was a significant 
association between high stromal DKK3 gene expression and poor outcome (Figure 1e). Analysis of 
human BC tissues showed that stromal DKK3 expression was restricted to vimentin-positive cells 
(Figure 1f), an expression pattern characteristic of CAFs12, 13. To investigate the cell of origin of DKK3 
expression, we isolated different cell populations of murine MMTV-PyMT mammary carcinomas 
(Supplementary Figure 1c&d, see Methods for details). Dkk3 expression was restricted to CAFs 
(Figure 1g). Similar findings were obtained in a human setting14 (Supplementary Figure 1e). Stromal 
DKK3 expression in human tumours positively correlated with the expression of CAF markers ACTA2, 
FN1 and FAP (Figure 1h), supporting a link between DKK3 and CAFs. As DKK3 was restricted to CAFs 
in tumours, we investigated the prognostic potential of whole tumour DKK3 expression. These 
analyses indicated a significant correlation between DKK3 gene expression and poor outcome in ER-
negative BC patients, as well as in colon and ovarian cancer patients (Figure 1i).  
DKK3 is a HSF1 target gene upregulated in CAFs 
To investigate DKK3 in tractable models, we isolated CAFs from murine mammary carcinomas and 
human breast, colon and ovarian cancers, as well as normal tissue counterparts (NFs). We observed 
consistent upregulation of DKK3 mRNA and protein levels in CAFs compared to NFs and cancer cells 
(Figure 2a&b and Supplementary Figure 2a&b). Comprehensive analysis of these models indicated 
that DKK3 expression was stronger in FAP-positive CAFs (Supplementary Figure 2b-d) but not 
necessarily associated with DKK3 secretion (Figure 2b). Noteworthy, the Dickkopf gene DKK2 also 
showed a significant enrichment in the cancerous stroma of some tumour types (Supplementary 
Figure 1a). However, DKK2 expression was not restricted to CAFs in murine or human tumours 
(Figure 1g and Supplementary Figure 1d&e), nor upregulated in murine or human CAFs when 
compared to NFs (Figure 2a&b and Supplementary Figure 2b). In addition, no association between 
DKK2 expression and poor outcome was observed in ER-negative BC, colon and ovarian cancer 
patients (Figure 1i). For these reasons, we decided to focus on studying the role of DKK3 in CAFs.    
To investigate the mechanism leading to DKK3 upregulation in CAFs, we first analysed the ChEA 
Transcription Factor Binding Site dataset in the Enrich database15, 16. This informed of 58 
transcription factors that potentially bind the DKK3 promoter (Figure 2c). Of these, HSF1 was the 
only factor to positively modulate DKK3 expression in perturbation assays17. This was further 
confirmed in two independent datasets involving Hsf1 deletion in fibroblasts6, 18 (Supplementary 
Figure 2e). HSF1 is a transcription factor that can be activated by stresses such as oxidative stress, 
nutrient-deprivation and protein misfolding19, which are commonly found in the tumour 
microenvironment. HSF1 has been associated to aggressive CAF behaviours by its ability to drive a 
transcriptional program that supports the malignant potential of cancer in a non-cell-autonomous 
way6. Silencing Hsf1 expression reduced Dkk3 mRNA and protein expression in CAFs (Figure 2f&g). 
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Furthermore, HSF1 activity strongly correlated with DKK3 gene expression in the stromal 
compartment of human tumours (Figure 2h). Next, we performed chromatin immunoprecipitation 
using anti-HSF1 antibodies and extracts from murine NF and CAFs. Figure 2i shows that Hsf1 was 
significantly more associated with the bona fide HSF1 target gene Rilpl in CAFs. Further, Hsf1 
interacted with promoter and enhancer regions of the Dkk3 locus, and this association was 
significantly increased in CAFs.  
DKK3 modulates pro-tumorigenic functions in CAFs 
To investigate the functional relevance of DKK3 we silenced Dkk3 expression in murine CAF1 with 2 
independent RNAi (Figure 3a). Knocking-down Dkk3 did not affect the expression of genes 
associated to CAF phenotypes (Figure 3b). However, the ability of CAFs to contract collagen gels, a 
measure of their matrix remodelling capacity, was dependent on Dkk3 expression (Figures 3c). 
Decreased gel contraction in Dkk3-siRNA CAFs was associated with thinner collagen fibres (Figures 
3d) and a significant decrease in matrix stiffness (Figure 3e). Similar findings were obtained in CAF5 
(Supplementary Figure 3a), a CAF line that did not secrete Dkk3 (Figure 2b). For long-term 
functional analyses, we generated Dkk3 knock-out CAFs (CAF-KO) and CAF-KO re-expressing Dkk3 
(CAF-KO-REC)(Supplementary Figure 3b and Figure 3f). Validating our previous results, Dkk3-null 
CAFs presented significantly less ECM remodelling activity (Supplementary Figure 3c&d). In three-
dimensional (3D) co-culture models20 (Figure 3g), CAFs promoted cancer cell invasion and growth of 
murine MMTV-PyMT TS1 cancer cells, and this ability was dependent on Dkk3 expression (Figure 
3h&i). These results were further validated using alternative approaches (i.e. matrigel on top) 
(Supplementary Figure 3e&f) and in human patient-derived CAFs from breast, colorectal and 
ovarian cancers (Supplementary Figure 4). Conversely, forcing DKK3 expression in NFs 
(Supplementary Figure 5a) significantly increased their abilities to remodel collagen matrices and 
promote TS1 invasion (Supplementary Figure 5b&c). In CAFs, HSF1 promotes tumour growth by 
inducing the production of secreted factors such as TGFβ and SDF16. Using recombinant DKK3 and 
CAF-derived conditioned media from WT, KO and KO-REC CAFs we observed that secreted DKK3 had 
no effect on cancer cell proliferation and motility (Supplementary Figure 5d). Validating these 
results, we observed no significant differences in cancer cell proliferation or motility between cells 
treated with conditioned media from CAF1 (detectable secreted DKK3, as per Figure 2b) or CAF5 (no 
detectable secreted DKK3), or in the presence of a blocking antibody against DKK3 (Supplementary 
Figure 5e). In addition, secreted DKK3 was not able to recover the functional defects associated to 
loss of DKK3 in CAFs (Supplementary Figure 5f). Thus, DKK3 is a novel HSF1 target gene that 
regulates ECM remodelling and associated cancer cell growth and invasion; unlike other HSF1 target 
genes such as TGFβ or SDF1, DKK3 does not have any apparent secreted function.  
DKK3 is required for the tumour promoting activities of CAFs in vivo 
In vivo (Figure 4a), we observed that tumours arising from cancer cells co-injected with KO-CAFs 
grew significantly more slowly than those of mice co-injected with WT-CAFs or KO-REC-CAFs, leading 
to increased survival (Figure 4b&c). Conversely, ectopic expression of DKK3 in NF significantly 
increased their ability to promote tumour growth in vivo (Supplementary Figure 5g). Histological 
analysis revealed that TS1+WT-CAF or TS1+KO-REC-CAF tumours shared a poorly differentiated 
morphology and invasive phenotypes typical of high-grade tumours, with loss of basal lamina (i.e. 
laminin staining), despite having similar number of αSMA-positive CAFs (Figure 5d). In contrast, 
TS1+KO-CAFs tumours had a more differentiated architecture where cancer cell acini where 
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surrounded by laminin-rich areas. Fibronectin and Masson’s trichrome staining revealed increased 
ECM deposition at the tumour border in TS1+WT-CAF and TS1+KO-REC-CAF tumours, suggesting a 
higher reactive stroma. Second-harmonic generation (SHG) imaging confirmed these findings as 
TS1+WT-CAFs tumours presented a higher content of collagen fibres than TS1+KO-CAF tumours 
(Figure 5f). These ECM characteristics have been linked with aggressive CAF phenotypes as they 
promote cancer cell motility and local invasion21, 22. In agreement, we observed areas at the tumour 
border where cancer cells were invading in TS1+WT-CAFs tumours (Figure 5f, asterisk). Using 
intravital imaging we confirmed this as co-injection of TS1 cells and WT-CAFs produced tumours 
where both cancer cells and CAFs were highly motile (Supplementary Movie 1; Figure 5g&h). In 
contrast, motility in tumours with KO-CAFs was severely impaired (Supplementary Movie 2; Figure 
5h).  
DKK3 in CAFs potentiates Wnt/β-catenin and YAP/TAZ signalling 
To understand the molecular mechanism whereby DKK3 exerts its functions and how HSF1 connects 
to other signalling pathways, we performed global transcriptomic profiling of murine CAFs after 
Dkk3 silencing. Gene set enrichment analysis23 revealed a significant decrease in the expression of 
genes associated with Wnt/β-catenin and YAP/TAZ activities (Figure 5a, Supplementary Figure 6a 
and Supplementary Table 1). β-catenin and YAP/TAZ are transcriptional regulators with paramount 
roles in development and cancer24, 25. In CAFs, YAP establishes a transcriptional program that 
enhances matrix remodelling and invasion of neighbouring cancer cells7. β-catenin plays a pivotal 
role in fibrotic disorders26, but its relevance in modulating CAF functions is still not well understood. 
Dkk3 knock-down decreased levels of non-phosphorylated (active) β-catenin and TAZ levels (Figure 
5b), reduced nuclear YAP/TAZ localization (Figure 5c) and inhibited β-catenin and YAP/TAZ 
transcriptional activity (Figure 5d). These findings were confirmed using Dkk3 knock-out/recovery 
system (Supplementary Figure 6b&c) and patient-derived CAFs (Supplementary Figure 6d-f). 
Conversely, ectopic expression of DKK3 in human NFs increased non-phosphorylated (active) β-
catenin and YAP/TAZ levels (Supplementary Figure 6g). Furthermore, we observed reduced β-
catenin and YAP staining in DKK3-null CAFs in vivo (Figure 5e&f), and DKK3 expression significantly 
correlated with YAP/TAZ and β-catenin signatures in human cancer stroma (Figure 5g). We 
confirmed that β-catenin and YAP/TAZ were activated in murine and human CAFs (Figure 5h and 
Supplementary Figure 7a&b), and in the stroma of breast, colorectal and ovarian cancers 
(Supplementary Figure 7c).  
DKK3 regulates CAF functions via YAP/TAZ 
Using our battery of functional assays we tested whether DKK3 was regulating CAF functions via 
YAP/TAZ and/or β-catenin. Contrary to YAP/TAZ silencing, knocking-down β-catenin (Figure 6a) had 
no effect in the ability of CAFs to contract collagen-rich matrices (Figure 6b), or promote cancer cell 
invasion and growth in 3D (Figure 6c&d). Loss of YAP/TAZ function in CAFs leads to MLC2 and Src 
inactivation and reduced actomyosin contractility, which affects the ability of CAFs to remodel the 
ECM7. Dkk3 knock-down was associated with reduced phospho-MLC2 and phospho-Src levels 
(Supplementary Figure 7d). β-catenin siRNA treatment did not affect MLC2 or Src activation (Figure 
6a), suggesting that DKK3 loss-of-function is primarily associated to its effect on YAP/TAZ activity. 
Confirming this, expression of a constitutively active mutant of YAP in Dkk3-null CAFs was able to 
recover their gel remodelling and cancer cell growth promoting abilities (Figure 6e&f). Both DKK3 
and YAP gain-of-function phenotypes were associated with reactivation of actomyosin contractility 
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and Src (Figure 6g). Overall, these data supported a model where HSF1 in CAFs leads to DKK3 
upregulation, which in turn potentiates YAP/TAZ activity leading to increased ECM remodelling and 
promotion of cancer cell growth and invasion (Figure 6h). In agreement, we observed that silencing 
Hsf1 in CAFs led to β-catenin and YAP/TAZ inactivation (Figure 6i and Supplementary Figure 7e) and 
was associated with a reduction in the matrix remodelling activity of CAFs (Figure 6j). However, 
these defects were prevented by constitutive expression of DKK3 or YAPS5A.  
DKK3 potentiates canonical Wnt signalling in CAFs 
We next investigated the molecular mechanism whereby DKK3 modulates YAP/TAZ. We observed 
that the expression levels of key regulators of YAP/TAZ function, MST1/2 and LATS kinases27, was 
marginally affected in one of the Dkk3-null clones (i.e KO.9) when compared to wild-type and KO-
REC CAFs (Supplementary Figure 8a). However, analysis of YAP S127 phosphorylation, the main 
maker of Hippo activity over YAP27-29, showed no differences after DKK3 modulation. This suggested 
that DKK3 might be acting independently of Hippo signalling. To confirm this, we silenced LATS1&2 
expression in wild-type and KO.9 CAFs and assessed CAF functions (Supplementary Figure 8b). 
Silencing LATS1&2 increased the abilities of CAFs to remodel gels and promote cancer cell growth 
(Supplementary Figure 8c&d), in line with their negative role in YAP function. However, the 
presence or absence of DKK3 did not significantly alter the effect of inhibiting Hippo signalling in CAF 
activities or YAP/TAZ levels, excluding a role for Hippo kinases in YAP/TAZ activation through DKK3.   
Recent studies have shown that, similar to β-catenin, YAP/TAZ stability and function are positively 
modulated in response to canonical Wnt signalling30, 31. Thus, association of LRP5/6 co-receptors 
with Axin1 in response to Wnt stimulation displaces β-catenin and YAP/TAZ from the destruction 
complex. In the absence of LRP5/6 signal, Axin1 targets β-catenin and YAP/TAZ for degradation. 
Gene expression analyses indicated that modulating DKK3 expression levels did not alter the 
expression of Wnt signalling regulators (Supplementary Figure 8e). However, our previous data 
suggested that DKK3 depletion/ectopic expression was affecting β-catenin and YAP/TAZ protein 
expression (Supplementary Figures 6b&g and Supplementary Figure 8a). To confirm whether DKK3 
was affecting the activity of the destruction complex, we performed cycloheximide-chase assays. 
Figure 7a shows that the protein stability of β-catenin and YAP/TAZ was severely affected in the 
absence of DKK3. Further analyses revealed that LRP6 levels at the cell surface were diminished 
when Dkk3 was knocked-out (Figure 7b), suggesting that DKK3 was affecting YAP/TAZ activity and 
CAF functions at the level of LRP5/6. In agreement, targeting Lrp5/6 expression in WT-CAFs 
(Supplementary Figure 8f), attenuated β-catenin and YAP activation (Figure 7c and Supplementary 
Figure 8f) and diminished their tumour promoting activities (Figure 7d&e). Yet, silencing Lrp5/6 
expression in Dkk3-null CAFs had no functional consequences. Inhibiting canonical Wnt signalling 
with XAV93932 yielded similar results (Supplementary Figure 7g&h), suggesting that this was a 
canonical Wnt-related function. To further confirm this, we investigated the role of DKK3 in CAFs 
after Wnt ligand stimulation. We observed that stimulation of wild-type and Dkk3-null CAFs with 
canonical Wnt ligand Wnt3a induced a significant increase in their basal (i.e. low serum) gel 
remodelling activities, whereas non-canonical Wnt5a stimulation had no effect (Figure 7f). Even 
though DKK3 was not absolutely required for CAFs to respond to Wnt3a, the gel remodelling 
activities of CAFs after Wnt3a stimulation were significantly reduced in the absence of DKK3. 
Importantly, these effects were concomitant with β-catenin and YAP activation (Figure 7g&h), 
indicating that DKK3 promotes YAP/TAZ signalling by potentiating Wnt signalling in CAFs.  
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DKK3 disable the negative Wnt regulator Kremen1&2 in CAFs 
Dickkopf proteins have been shown to inhibit Wnt signalling by triggering LRP5/6 internalization 
through formation of a ternary complex with Kremen1/2 receptors9, 10. This is in striking contrast 
with our observations on the role of DKK3 in CAFs, and underline the functional differences of 
Dickkopf proteins reported in other systems33-35. DKK3 is an unusual member of the family as it 
does not interact with LRP5/6 but still can interact with Kremen9, 10, 36. Using HEK293T cells, it has 
been proposed that DKK3-Kremen interaction negatively affects surface expression of Kremen, 
which may favour canonical Wnt signalling by still unclear mechanisms36. We first confirmed that 
Kremen1 but not LRP6 immunoprecipitated with DKK3 in CAFs (Figure 8a). In addition, DKK3-
Kremen1 co-localised to internal structures; however, after DKK3 silencing Kremen1 localised to the 
cell periphery (Figure 8b), in an opposite pattern to LRP6 localisation (Figure 8c). Interestingly, DKK3 
expression was inversely associated to changes in Kremen1&2 protein expression (Figure 8d). mRNA 
levels of Kremen1/2 were not altered after Dkk3 silencing (Supplementary Figure 8e), suggesting a 
post-translational regulation. Cycloheximide-chase assays confirmed that Kremen1 was less stable in 
WT-CAFs than in Dkk3-null CAFs whereas LRP6 stability was increased (Figure 8e). Our data 
suggested that disabling Kremen activity may restore LRP6 functions in the absence of DKK3 
expression. In agreement, silencing Kremen receptors in Dkk3-null CAFs (Figure 8f) increased their 
abilities to remodel gels (Figure 8g) and promoted cancer cell growth and invasion (Figure 8h&i). 
These changes were associated with concomitant re-localisation of LRP6 to the cell surface (Figure 
8j) and reactivation of YAP/TAZ and β-catenin signalling (Figure 8f&k). Conversely, knocking-down 
Kremen1&2 in DKK3-expressing CAFs had no functional consequences (Supplementary Figure 8i). 
Overall, our mechanistic analyses support a model whereby DKK3 stabilises the cell-surface levels of 
LRP6 by uncoupling LRP6 from the Kremen-mediated internalization machinery. In turn, DKK3-
mediated LRP6 regulation leads to activation of β-catenin and YAP/TAZ, with the latter being the 
main mediator of DKK3 functions (Figure 9).  
DISCUSSION 
Secreted Dickkopf proteins are emerging as unpredicted tumour-promoting factors due to their 
immune-suppressive activities33, 35, 37. Here, we demonstrate that the family member DKK3 can also 
promote aggressive behaviours in CAFs in a cell autonomous manner. DKK3 reduces YAP/TAZ 
degradation by potentiating Wnt signalling, thus acting in parallel to YAP/TAZ regulation via 
mechanotransduction38, 39. DKK3 also activates β-catenin in CAFs and we document that cancer 
stroma and CAFs present increased β-catenin activity. However, inhibition of β-catenin by RNAi did 
not affect CAF-mediated ECM remodelling, cancer cell growth and invasion. Further studies are 
required to determine if β-catenin modulates other pro-tumorigenic functions in CAFs such as 
potentiating the tumour initiating capacity of cancer cells or immune suppression13. The role of DKK3 
as a positive regulator of canonical Wnt is in contrast to the well documented role of other Dickkopf 
family members. Here, we provide mechanistic insights into these differences. Contrary to what 
has been shown for DKK1 and DKK2, we show that DKK3 does not bind LRP6 co-receptor in CAFs, 
and therefore cannot fulfil the bona fide antagonist role of Dickkopf proteins in canonical Wnt 
signalling. By contrast, we demonstrate that DKK3 perturbs the negative regulator Kremen and 
enhances Wnt signalling via LRP6.  
Whilst several CAF effectors have been identified, an unanswered question is how the coordination 
of different signalling pathways involved in their control is established. Our results suggest that 
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HSF1-dependent DKK3 upregulation could be a response of stromal fibroblasts to stresses found in 
the tumour microenvironment. In turn, DKK3 expression promotes fibroblast activation as it sustains 
crucial activating pathways. Thus, DKK3 expression potentiates canonical Wnt signalling, leading to 
reduced YAP/TAZ degradation. This leads to YAP/TAZ activation, ECM stiffening and the generation 
of aggressive tumour microenvironments. We propose that this may be a mechanism for tumour-
promoting CAFs to be selected as tumour progresses and a plausible mechanism explaining its 
significant enrichment in cancer stroma. Further work is still required to understand the processes 
modulating HSF1 activity in CAFs, and whether the axis HSF1-DKK3-YAP is also relevant in other 
systems.  
To conclude, we identify a key role of DKK3 in tumour stroma. It is required for many of the pro-
tumorigenic functions of CAFs, including matrix stiffening and cancer cell growth and invasion. High 
levels of DKK3 in the stroma are sustained by HSF1, potentiate Wnt signalling and reduce YAP/TAZ 
degradation. Thus, DKK3 acts as a crucial integrator of key molecular players modulating the 
emergence of tumour-promoting phenotypes in CAFs.   
 
METHODS 
Mouse strains.  
Transgenic FVB/n mice expressing the Polyoma Middle T antigen oncogene under the Mouse 
Mammary Tumour Virus promoter (MMTV-PyMT)40 were used for tumour cell isolation and FACS 
analysis. Wild-type FVB/n and CD-1 Nude mice (Charles River) were used as recipients for tumours. 
All animals were kept in accordance with UK regulations under project license PPL80/2368. 
Cell lines.  
Established murine fibroblasts from FVB/n normal mammary glands (NFs) and MMTV-PyMT 
mammary carcinoma (CAFs) have been previously described7, 41. Human fibroblasts from normal 
mammary glands and breast carcinomas were provided by Julia Tchou (University of Pennsilvania, 
USA)42 and Clare Isacke (Institute of Cancer Research, UK). Human fibroblasts from rectal carcinomas 
(RC11), colon carcinomas (CAF25) and adjacent normal tissue (NAD-D) were provided by Danijela 
Vignjevic (Institute Curie, France). Human fibroblasts from ovarian carcinoma (EOC.TIL.04) were 
provided by Marco Donia (University of Copenhagen, Denmark). Human CAFs from cervical (Cer-
CAF) squamous cell carcinoma have been previously described7. Human primary fibroblasts were 
expanded and immortalized using hTERT virus (pCSII vector backbone) followed by selection with 
hygromycin. All resulting fibroblast populations were assessed for fibroblast and CAF marker 
expression and thoroughly characterized7. All fibroblasts were cultured in DMEM (Sigma), GlutaMax 
(Gibco), 10% FBS, 1% insulin-selenium-transferrin (ITS, Gibco). MMTV-PyMT TS1 murine breast 
cancer cells were used in most assays and to generate tumours in syngeneic FVB/n mice. Human 
breast cancer cell line BT20 was cultured in MEM plus GlutaMAX and 10% FBS. Colon cancer cell line 
HCT116 was grown in McCoy 5A (with 1% GlutaMAX and 10% FCS). Ovarian cancer cell line SKOV3 
was grown in RPMI with 1% GlutaMAX, 10% FBS and 1% Pyruvate. All cell lines were grown in a 
standard humidified 5% CO2 incubator at 37° C and tested negative for mycoplasma infection with 
MycoAlertTM (Lonza). CAFs and cancer cell lines were fluorescently labelled using the following 
lentiviral vectors, as indicated: EGFP-CAAX pCSII-IRES2-hygro, ECFP-CAAX pCSII-IRES2-hygro, 
ORANGE-CAAX PCSII-IRES2-hygro, mCherry-CAAX pCSII-IRES2-hygro and pCSII-IRES2-blasti-eGFP. 
cDNA, RNAi and reagents.  
DKK3 (a kind gift by Peter Berger, University of Innsbruck) was ectopically expressed in CAF/NFs lines 
using a pLENTI6 lentiviral vector system. shRNAs targeting human DKK3 were cloned into the 
lentiviral vector pLKO.1-TRC-cloning vector (Addgene, Plasmid #10878) at AgeI/EcoRI restriction sites 
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according to the online Addgene protocol (www.addgene.org/tools/protocols/plko). shRNA 
sequences were obtained from the GPP Web Portal (Broad Institute, 
http://portals.broadinstitute.org/gpp/public/). A list of the respective shRNA sequences can be 
found in Supplementary Table 3. siRNAs were purchased from Dharmacon and are listed in the 
Supplementary Table 4. For in vitro treatments the following growth factors and drugs were used: 
recombinant human DKK3 (R&D, 1118-DK-050), XAV939 (Sigma, X3004), Cycloheximide (Sigma, 
C7698), Wnt3a (R&D, 5036-WN-010), Wnt5a (R&D, 645-WN-010). Lentiviral plasmid for expression 
of mutant YAP was 5SA-YAP1-YFP vector (kind gift of Eric Sahai, Crick Institute).  
Generation of CRISPR knock-out cell lines.  
The CRISPR plasmid U6-gRNA/CMV-Cas9-GFP containing a guide RNA targeting mouse DKK3 was 
purchased from Sigma (MM0000346166). CAF1 cells (CAF-WT) were transfected with the plasmid 
using Lipofectamine (Life Technologies) following manufacturer’s instructions and GFP positive cells 
were single sorted into 96 well plates after 24 h. GFP-negative clones were also sorted as controls 
(e.g. WT.9). Individual cell clones were expanded and the DKK3 locus targeted by CRISPR was 
sequenced for knockout validation. In addition, loss of DKK3 protein expression was also confirmed 
by immunoblotting to generate DKK3-null CAFs (CAF-KO). DKK3-null clones were infected with DKK3-
expressing lentivirus to generate KO-CAFs re-expressing DKK3 (CAF-KO-REC). 
Conditioned media.  
CAF-derived conditioned media was generated by culturing a confluent monolayer of cells in DMEM 
2.5% or 5% FBS for 48 h. Media was then recovered and filtered through a 0.22 μm filter and used as 
indicated. For detection of DKK3 in the conditioned media, 50 μL of StrataClean resin (Agilent 
Technologies UK Ltd, 400714) were added to 1 mL of media. Each sample was vortexed for 1 min, 
left at RT for 1 min and spun 15,000 x g for 5 min at 4˚C. The supernatant was then removed and the 
beads were prepared in protein sample buffer to be resolved in SDS-PAGE. 
Transfections.  
Fibroblasts were seeded at 60% confluency and transfected using DharmaFECT 1 (Dharmacon) for 
siRNA (100 nM final concentration), and Lipofectamine (Life Technologies) for plasmids following 
manufacturer’s instructions. Cell lines stably expressing cDNA (DKK3 or GFP/CFP/mCherry) or 
shRNAs were generated by lentiviral infection followed by puromycin selection for 2 weeks (2 μg 
mL−1). Alternatively, fluorescent-labelled cells were sorted by FACS. 
ECM-remodelling assay.  
To assess force-mediated matrix remodelling, 7.5 × 104 murine fibroblasts or 3-5 x 104 human 
fibroblasts were embedded in 120 µL of a mixture of collagen I (BD Biosciences) and ECM gel mixture 
(Sigma) yielding a final collagen concentration of approximately 4.6 mg mL−1 and a final ECM gel mix 
concentration of approximately 2.2 mg mL−1 (Collagen-rich matrix hereafter). Once the gel was set, 
cells were maintained in fibroblasts medium. Gel contraction was monitored daily by scanning the 
plates. Unless stated otherwise, the gel contraction value refers to the contraction observed after 2 
days. To obtain the gel contraction value, the relative diameter of the well and the gel were 
measured using ImageJ software, and the percentage of contraction was calculated using the 
formula 100 × (well area – gel area) / well area. When indicated, gels were fixed in 4% 
paraformaldehyde (PFA) for 16 h and processed for immunofluorescence. Backscattered light 
(reflectance) was collected to image the matrix surrounding cells. Alternatively, collagen second 
harmonic generation (SHG) signal was acquired by exciting with an 880 nm pulsed Ti–Sapphire laser 
and acquiring emitted light at 440 nm using a Leica SP8 microscope.  
3D co-culture.  
The 3D co-culture spheroid assay was adapted from Dolznig et al20. In short, cancer cells were 
seeded in low numbers (200 cells per well TS1-mCherry, 50 cells per well HCT116-mCherry, 150 cells 
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per well BT20-GFP and SKOV3-orange) in ultra-low adherent cell culture plates (Corning) to form 
spheroids for 48 h. The spheroids were collected and mixed with 1 x 105 fibroblasts. The spheroid 
and fibroblast suspension was centrifuged at 200 x g for 4 min and the supernatant was carefully 
removed. The pellet was first re-suspended in 30 µL of medium and then mixed with 270 µL of 
Collagen-rich matrix. The 300 µL gel containing the spheroids and fibroblasts was seeded in a glass-
bottom 3.5 cm MatTek dish. A nylon filter (Nylon NET filters 120 μm, Merck Millipore) with a hole of 
approximately 1 cm diameter cut out at the centre was added to prevent excessive gel contraction. 
The gel was set for 1 h in the incubator at 37˚C and cancer cell medium was added. The spheroids 
were incubated for 5-7 days (3-5 days for studies involving siRNA-transfected CAFs) and then fixed 
with 4% PFA and either imaged directly or stained additionally with DAPI and phalloidin-TRITC or 
phalloidin-FITC. Samples were mounted and analysed using a Leica SP8 confocal microscope. 
Confocal sections were acquired for individual spheroids from bottom to top, z-stack projections 
were analysed using ImageJ and data analysed in GraphPad Prism. The invasion index was calculated 
by measuring the total area over which cancer cells had dispersed (including invading and non-
invading cells) and the area of non-invading cells (1 – [non-invading area/total area]). To calculate 
tumour growth index, area covered by cancer cells in each spheroid was calculated.  
Matrigel on Top (MOT) co-culture.    
24-well MatTek glass bottom plates were pre-coated with 100 µL of Matrigel. Next, 6 x 104 CAFs per 
well were seeded, unless otherwise stated. After 1 h, fluorescently labelled cancer cells (2 x 104  per 
well) were seeded and allowed to adhere for 4 h. Growth medium was exchanged to DMEM 2.5% 
FCS and 2% Matrigel and co-cultures were allowed to grow for 48 h, or up to 120 h for the ovarian 
cells. Co-cultures were then fixed in 4% PFA and analysed by confocal microscopy. Images were 
analysed using ImageJ and data analysed in GraphPad Prism. To calculate cancer cell growth index, 
area covered by cancer cells in each field of view was calculated.  
Atomic force microscopy.  
To assess the elastic modulus of gels remodelled by fibroblasts, 75 × 103 fibroblasts were embedded 
in 100 µL of Collagen-rich matrx and seeded on ultra-low attachment 96 well-plate (Costar). Once 
the gels were set, they were maintained in fibroblast medium. After 3 days, the elastic modulus of 
the gels was measured as previously described7. Gels were gently lifted from their well and fixed in 
the centre of 50 mm glass bottom Petri dishes using cyanoacrylate superglue. Once glued, Leibovitz 
L-15 medium (Invitrogen) supplemented with 10% FCS was added to the dish. AFM measurements 
were performed with a JPK Nanowizard-I (JPK instruments, Berlin, Germany) interfaced to an 
inverted optical microscope (IX-81, Olympus). AFM cantilevers with pyramidal tips (MLCT, Bruker, 
Karlsruhe, Germany) and nominal spring constants of 0.07 Nm−1 were modified by gluing 35 μm 
radius glass beads to the cantilever underside with UV curing glue (UV curing, Loctite, UK). Cantilever 
spring constants were determined prior to modification using the thermal noise method 
implemented in the AFM software (JPK SPM). Prior to any indentation tests, the sensitivity of the 
cantilever was set by measuring the slope of force-distance curves acquired on glass regions of the 
Petri dish. Using the optical microscope, the tip of the cantilever was aligned over regions in the 
middle of the gel and, for each gel, measurements were acquired in 30-40 locations ~100 μm apart. 
Force-distance curves were acquired with an approach speed of 5μm.s−1until reaching the 
maximum set force of 3 nN. After the experiment, the elastic moduli were extracted from the force-
distance curves by fitting the contact portion of curves to a Hertz contact model. For each force-
distance curve, goodness of fit was evaluated by calculating r^2 values and only fits with r^2>0.80 
were retained for further analyses (representing on average 80% of the acquired force-curves). 
Immunofluorescence.  
Cells were fixed in 4% PFA for 1 h and permeabilised by incubation in PBS 0.2% Triton 100 (Sigma) at 
RT for 20 min. For HSF1 immunofluorescence, cells were permeabilised by incubation in PBS 0.5% 
NP-40 (Sigma) at 4°C for 20 min (twice), in PBS 0.3% Triton 100 (Sigma) at RT for 20 min and in PBS 
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0.1% Triton 100 at RT for 15 min (twice).  Where indicated (non-permeabilised), this step was not 
performed. Samples were blocked for 60 min at RT in blocking solution: 4% BSA PBS 0.05% Tween20 
(Sigma). Then, cells were incubated with primary antibody in blocking solution in a wet chamber 
overnight at 4°C. After 3 washes of 15 min in PBS, secondary antibody in blocking solution was 
added for 3 h. After 3 washes of 15 min in PBS, samples were mounted and analysed using a Leica 
SP8 confocal microscope. To quantify β-catenin activation by immunofluorescence, for each field of 
view we calculated the area positive for active-β-catenin staining per cell using Volocity. These 
values were then normalized to the mean value of CAF-WT (murine CAFs) or control siRNA 
transfected cells (human CAFs). To quantify YAP and TAZ activation by immunofluorescence, we 
measured their nuclear localization using Volocity. Briefly, we calculated for each cell the total 
intensity of nuclear HSF1, YAP or TAZ staining (determined by the intensity within the region 
delimited by DAPI staining) and perinuclear staining (defined as a region encompassing two to seven 
pixels from the nucleus border). Nuclear/cytoplasmic YAP and TAZ ratios were calculated as the 
log10 of the total nuclear intensity/mean perinuclear region intensity per cell. For the analysis of 
human CAFs, nuclear/cytoplasmic YAP and TAZ ratios were normalized to the mean ratio of control 
siRNA transfected cells. Antibody description and working dilutions can be found in Supplementary 
Table 2.  
Tissue immunohistochemistry and immunofluorescence.  
For histological analysis, tumours were dissected into 10% neutral buffered formalin, embedded in 
paraffin blocks and serial sections were taken. Paraffin-embedded tissue sections were rehydrated 
before antigen retrieval using pH 6 sodium citrate buffer. After blocking endogenous peroxidase 
(DAKO peroxidase block), sections were incubated for 1 h at RT with primary antibodies. For DKK3 
staining, four antibodies (Abgent AP1523a, R&D AF1118, Sigma HPA011868 and Santa-Cruz H130) 
were tested for specificity using Western blot and cell pellets in control and DKK3-silenced CAFs, and 
then optimised for TMA analysis. Both Sigma and Santa-Cruz antibodies yielded satisfactory results. 
Data presented corresponds to Santa-Cruz DKK3 antibodies. Sections were incubated with secondary 
antibodies for 50 min at RT, treated with 3,30-diaminobenzidine and counterstained with 
haematoxylin. Images were acquired using a Digital Slide Scanner (Hamamatsu Photonics). Images 
were analysed using Volocity and data analysed in GraphPad Prism. For each staining, positive area 
was calculated and normalized to the total area for all slices processed.  For immunofluorescence, 
after antigen retrieval sections were incubated with 0.2% Triton X-100 (Sigma) 10% Goat serum 
(Sigma) blocking solution for 1 h RT.  Sections were incubated overnight at 4°C with primary 
antibodies diluted in PBS. After washing, sections were incubated with fluorescent-conjugated 
secondary antibodies (AlexaFluor) diluted in PBS for 1 h at RT. Confocal images were captured using 
a Leica SP8 microscope. Quantitative analysis of YAP and β-catenin staining in the tumour stroma 
was performed using Volocity software. Briefly, fibroblasts were identified using automated 
threshold based on S100A4 staining. The mean intensities of YAP and β-catenin were then 
measured. In addition to haematoxylin and eosin staining and Masson's trichrome staining, antibody 
description and working dilutions can be found in Supplementary Table 2.  
Tissue microarrays.  
The following tissue microarrays were purchased from US Biomax, Inc: breast cancer (BR1504b), 
colon cancer (CO2083), and ovarian cancer (OV2001a). Formalin-fixed, paraffin-embedded (FFPE) 
sections were deparaffinized, blocked with 3% H2O2 and antigen retrieval was performed using a 
pressure cooker with Dako citrate buffer (pH 6.0). Slides were incubated with DKK3 antibody (DKK-3 
H-130, Santa Cruz, sc-25518) for 1 h at RT. Visualization was achieved with 3,30-diaminobenzidine as 
a chromogen (Dako Envision+ System). Images were acquired using a Digital Slide Scanner 
(Hamamatsu Photonics). DKK3 staining was quantified using the weighted Histoscore method to give 
a value of 0–30043.  
Tissue digestion for cell isolation and FACS analysis.  
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MMTV-PyMT tumours were minced with a scalpel and digested with a mixture of DNase and 
Liberase (Roche Diagnostics). On enzymatic digestion, samples were passed through a 100 μm filter. 
Cells were incubated for 5 min at RT in 2  mL NH4Cl solution (0.8% in H2O) to eliminate red blood 
cells. Cells were then directly used for FACS staining and sorted with a FACSAria flow cytometer (BD 
Biosciences). Single cell suspensions of tumour cells were labelled with FITC Rat Anti-Mouse 
CD45 Clone 30-F11 (BD Pharmingen™, 553079), APC Rat Anti-Mouse CD31 Clone  MEC 13.3  (BD 
Pharmingen™, 561814), PE/Cy7 anti-mouse CD326 (Ep-CAM) (BioLegend, 118215) and PE anti-
mouse CD140a (PDGFRa) (BioLegend, 135905). For cell sorting, four populations (CD45+ for immune 
cells, CD31+ for endothelial, EPCAM+ for epithelial and PDGFRA+ for CAFs) were collected and 
processed for RNA extraction and qRT-PCR.  
Proliferation analysis.  
For proliferation analyses with conditioned media, TS1 cancer cells were seeded at 5,000 per well in 
a 24-well plate in duplicates and incubated with media containing 5% FBS (vehicle) or 5% FBS plus 
100 ng mL−1 recombinant DKK3 (rDKK3), or with CAF conditioned medium (5% FBS) for 72 h. Where 
indicated, blocking antibody for DKK3 (R&D AF1118) or isotype control (R&D AB-108-C) were added 
at 1 µg mL−1 . AlamarBlue® assay was used according to manufacturer’s instructions to compare cell 
growth and viability. 
Scratch Wound healing assay.  
TS1 cancer cells were cultured to a confluent monolayer in 24-well plates. A straight scratch was 
made on the cell layer using a 200 µL tip across the centre of the well. Cell debris was removed by 
washing twice with PBS and cells were incubated with media containing 5% FBS (vehicle) or 5% FBS 
plus 100 ng mL−1 recombinant DKK3 (rDKK3), or with CAF conditioned medium (5% FBS). Where 
indicated, blocking antibody for DKK3 (R&D AF1118) or isotype control (R&D AB-108-C) were added 
at 1 µg mL−1 . Cell migration was monitored for 40 h using live cell imaging in the IncuCyte® (Essen 
Bioscience) in a standard humidified 5% CO2 incubator at 37° C. The wounded area at start and end 
of experiment was measured using ImageJ. Wound closure was calculated as the percentage of 
healed area (area at t0 minus area at t40) to the starting wounded area.  
Co-Immunoprecipitation.  
For Kremen1 and DKK3 co-inmunoprecipitations, CAFs expressing empty vector of Flag-DKK3 were 
lysed in immunoprecipitation lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton-X-100, 
10% glycerol, 2 mM EDTA, 25 mM NaF and 2 mM NaH2PO4) containing protease and phosphatase 
inhibitor. Lysates were pre-cleared using G-sepharose, incubated with anti-Flag antibody (rabbit) or 
IgG immobilized on G-sepharose beads at 4°C overnight. Beads were then washed 5 times with lysis 
buffer and eluted with 20 μL of 2x SDS sample buffer.  
Western Blotting.  
Protein lysates and immunoprecipitants were processed following standard procedures. Enhanced-
chemiluminescence signal was acquired using an Azure Biosystems c600. Exposures within the 
dynamic range were quantified by densitometry using ImageJ. Antibody description and working 
dilutions can be found in Supplementary Table 2. Immunoblot images in Figures and Supplementary 
Figures show molecular weight markers in kDa. Supplementary Figure 9 shows the uncropped 
images corresponding to the panels displayed in the main figures. 
Luciferase reporter assays.  
The following plasmids were used for luciferase reporter assays: TEAD-reporter construct (8xGTIIC-
luciferase, Addgene, Plasmid #34615), TOP-reporter construct (M50 Super 8x TOPFlash, Addgene, 
Plasmid #12456) and CMV-Renilla (pGL4.75[hRluc/CMV], Promega). CAFs were seeded in 6-wells 
plates at 70% confluency. Cells were transfected with 2 µg TOPFlash or TEAD-reporter and 100 ng of 
CMV-Renilla cDNA constructs using Lipofectamine 3000 according to the manufacturer's 
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instructions. Cells were lysed 48 h after transfection in 100 μL of lysis buffer (Promega). Aliquots of 
the cell lysates were used to read luciferase emission using Dual-Glo® Luciferase Assay System 
(Promega) according to the manufacturer's instructions. Luciferase activities were normalized to 
Renilla activity. 
Generation of syngeneic orthotopic tumors.  
MMTV-PyMT TS1 murine breast cancer cells were used to generate tumours in wild type FVB/n. 
Briefly, 106 TS1 cells and 3 x 106 CAF (WT, KO.9 or KO.9-REC) were suspended in 100 μL of 
PBS:Matrigel (50:50) and injected subcutaneously into 6-8 week old females. Tumour size was 
measured every other day using callipers. To calculate tumour volume the formula V = (length × 
width2) / 2 was used. Mice were killed once tumours reach the maximum allowed size.  
Intravital imaging.  
The implantation of an orthotopic mammary imaging window in CD-1 nude mice was performed as 
previously described 44. 48 h after surgical implantation of the imaging window, a mixture of 1 x 106 
CAFs (GFP) and 4 x 105 TS1 (CAAX-mCherry) cancer cells in a PBS:Matrigel solution (50:50) were 
injected under the window. Intravital 2-photon imaging was performed at specified time-points 
using a Leica SP8 microscope. Briefly, mice were anesthetized and tumours were excited with an 880 
nm pulsed Ti–Sapphire laser and emitted light acquired at 440 nm (collagen second harmonic 
generation, SHG) and 530 nm (GFP). In addition, a mCherry signal was acquired sequentially using 
confocal microscopy. During approximately 10-min intervals, 5 to 8 different regions were imaged 
simultaneously for 2 h for each tumour. In each region, a z-stack of 4-5 images (approximately 50 µm 
deep on average) was taken at a spacing of 10 μm between images, resulting in a time lapse three-
dimensional z-series for analysis. To analyse the collagen content, mean intensity of SHG signal of 
the top confocal plane for each z-stack was used. Moving cells were defined as those that moved 10 
μm or more during the length of each movie.  
RNA isolation and qRT-PCR.  
To obtain RNA from the different fibroblast populations, RNA was isolated using EZNA Total RNA Kit 
1 (Omega Bio-tek). Reverse transcription was performed using Precision NanoScript 2 Reverse-
Transcription-kit (PrimerDesign) and qPCR using PrecisionPLUS 2x qPCR MasterMix with ROX and 
SybrGreen (PrimerDesign). Expression levels of indicated genes were normalized to the expression of 
Gapdh, Rplp1 or Lamc2. Sequences of the oligonucleotides used for qRT-PCR are described in the 
Supplementary Table 5. For array analysis, RNA was isolated as described and processed in 
collaboration with Eurofins Genomics (GeneChip Mouse Gene 2.0 ST Array – details available on 
reasonable request).  
ChIP-qPCR.  
7-10 x 106 NF or CAF at subconfluency were fixed in 1% formaldehyde and sonicated using the 
Bioruptor Pico sonication device (Diagenode; B01060001) using 15 cycles (30 s on; 30 s off) at 
maximum intensity. Purified chromatin was then separated for: (i) immunoprecipitation using 
Dynabeads Protein G (Life Technologies: 10003D) coated with 8 µg and 4 µg of HSF1 antibody 
(ThermoFisher: RT-405-P, and Cell Signalling: 4356S respectively) per ChIP experiment; (ii) non-
immunoprecipitated chromatin, used as Input control; and (iii) assessment of sonication efficiencies 
using a 1% agarose gel. For the quantitative PCR briefly, reactions were carried out in 10 μL volume 
containing 5 μL of Sybergreen mix (Applied Biosystems; 4472918), 0.5 μL of primer (5 μM final 
concentration), 2.5 μL of genomic DNA and 2 μL of DNAse/RNAse – free water. A three-step cycle 
programme and a melting analysis were applied. The cycling steps were as follows: 10 s at 95°C, 30 s 
at 60°C and 30 s at 72°C, for 40 cycles. Enrichment of the immunoprecipitated sample was confirmed 
using positive and negative controls. The exact loci of the primers are as follows: negative control 
(gene desert): chr6:116908976-116909177; Dkk3 Promoter (P): chr7:112159485-112159638; Dkk3 
Ferrari et al  DKK3 in Cancer-associated fibroblasts 
Page 14 of 22 
 
Enhancer (E): chr7:112183116-112183344; Rilpl, within the gene (positive control): chr5:124510011-
124510190.  
Gene expression analyses of clinical datasets.  
Gene expression analyses of human tumour stroma were retrieved from NCBI Gene Expression 
Omnibus (GEO). Datasets are described in Supplementary Figure 1a and include: Finak (GSE9014, 
Breast), Karnoub (GSE8977, Breast), Yeoung (GSE40595, Ovary), Nishida (GSE35602, Colon), Saadi 
(GSE19632, Aesophagus), Costea (GSE38517, Oral SCC), Navab (GSE22863, Lung) and Sherman 
(GSE43770, Pancreas). Additional datasets include: GSE14548 (Breast cancer epithelia and stroma), 
GSE20086 (human breast NF and CAFs), GSE70468 (human colon NF and CAFs) and GSE35250 
(human ovarian NF and CAFs). In addition, the dataset describing the expression profiles of cell 
populations purified from human colorectal cancer (GSE39396) was also used. For Affimetrix-based 
arrays, probe-to-gene mapping was performed using Jetset 45; for the rest of the arrays, highest 
variance probes were selected. Probes mapping Dickkopf genes used for each array can be found in 
Supplementary Figure 1a. Unless otherwise stated, expression values for each gene were z-score 
normalised. For the analyses of YAP/TAZ and β-catenin signatures in tumour stromal datasets, we 
first generated CAF-specific YAP/TAZ and β-catenin signatures. Genes significantly downregulated in 
murine CAF1 after transfection with YAP/TAZ siRNA or XAV939 (β-catenin inhibitor) treatment were 
identified. In addition, we sought for genes specifically expressed by FAP-positive CAFs in human 
tumours using the GSE39396 dataset. This dataset describes the expression profiles of cancer cells, 
immune cells, endothelial cells and CAFs purified from human colorectal cancer. We identified genes 
significantly upregulated more than 1.5-fold in FAP-positive samples when compared to the rest of 
the samples. Genes from the YAP/TAZ and β-catenin signatures that overlapped with the genes in 
the FAP-positive signature were selected into CAF-specific signatures; the rest were selected into 
CAF-unspecific signatures. To calculate the gene-signature score in each sample, we used single 
sample Gene Set Enrichment Analysis (ssGSEA)46 Projection Software from the GenePattern platform 
developed by the Broad Institute of MIT and Harvard (USA) and available at  GenePattern 
(www.genepattern.broadinstitute.org), following the programs guidelines (log normalisation; 
weighting exponent 0.75). This analysis calculates separate enrichment scores for each pairing of 
sample and gene set. Each ssGSEA enrichment score represents the degree to which the genes in a 
particular gene set are co-ordinately up- or down-regulated within a sample. ssGSEA scores were z-
score normalised. For analyses of HSF1 signature, a similar approach was performed. The top 200 
genes downregulated between wild-type and Hsf1-null mouse embryonic fibroblasts (GSE56252) 
were identified and genes also present in the FAP-positive signature were selected to generate the 
HSF1 CAF-specific signature. 
Enrich database analysis.  
To identify putative transcription factors (TFs) regulating DKK3 expression we used the Enrich 
database15, 16 [http://amp.pharm.mssm.edu/Enrichr/]. We queried for DKK3 gene and retrieved the 
ChEA 2016 dataset to identify possible TFs that bind the DKK3 promoter, obtaining a list of 58 TFs 
(Supplementary Data 1). In addition, we retrieved the TF-LOF Expression from GEO dataset to obtain 
a list of TFs whose loss of function has been associated to changes in DKK3 expression 
(Supplementary Table 6).  
Survival Analyses.  
Analysis of clinical relevance of DKK3 expression was assessed using publicly available data from the 
Kaplan-Meir Plotter platform for breast and ovarian cancer 47, 48 (version 2014 and 2015, 
respectively), as well as the GSE17538 dataset for colorectal cancer 49. Probe-to-gene mapping was 
performed using Jetset 45. For survival analysis of ovarian cancer (progression-free survival), the 
highest quartile of gene expression was used to dichotomize the different tumours into high and low 
groups. Survival analyses for breast (recurrence-free survival) and colon (disease-specific survival) 
datasets, tumours were split into high and low based on median expression, respectively. For breast 
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cancer, further analyses of recurrence-free survival and distant-metastasis-free survival were 
performed based on ER-status and molecular subtype. Breast cancer disease-free survival analysis 
based on DKK3 expression in the tumour microenvironment was performed using the Finak Dataset 
50. Only ER-negative patients were analysed. Mean DKK3 expression was used to split tumours into 
high and low expression groups. 
Gene-set enrichment analyses (GSEA).  
Array data was processed and analysed using the Gene-set enrichment analysis software, developed 
by the Broad Institute of MIT and Harvard (USA) and available at www.broadinstitute.org, following 
the program guidelines. The specific settings applied in all analyses are: Number of Permutations 
(1000), Permutation Type (Gene set), Enrichment statistic (Weighted), Metric for ranking genes (t 
Test). Values represent the False Discovery Rate (-log2) and the Nominal Enrichment Score (NES) of 
each gene set. The list of the specific gene sets analysed and their sources are available 
in Supplementary Data 2.  
Statistical analyses.  
Statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc.). When n 
permitted, values were tested for Gaussian distribution using the D’Agostino-Pearson normality test. 
For Gaussian distributions, paired or unpaired two-tailed Student’s t-test and one-way ANOVA with 
Tukey post-test (for multiple comparisons) were performed. For non-Gaussian distributions, Mann-
Whitney’s test and Kruskal-Wallis test with Dunn’s post-test (for multiple comparisons) were 
performed. Unless stated otherwise, mean values and standard errors (SEM) are shown. Survival 
curves were estimated based on the Kaplan–Meier method and compared using a log-rank test. P 
values of less than 0.05 were considered statistically significant. Where indicated, individual p values 
are shown; alternatively the following symbols were used to describe statistical significance: *, P < 
0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001; n.s., non-significant.  
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FIGURE LEGENDS 
Figure 1. DKK3 is upregulated in the stroma of breast, colon and ovarian cancers. (a) Tukey 
boxplots showing z-score values of DKK3 mRNA expression in normal and cancerous stroma from 
breast, colorectal and ovarian cancers (Breast: normal, n=6; cancer, n=53. Colon: normal, n=4; 
cancer, n=13. Ovary: normal, n=8; cancer, n=31). (b) Representative images of DKK3 staining in 
breast, colorectal and ovarian cancers and normal tissues. Scale bar, 100 µm. (c) Tukey boxplots 
showing quantification of DKK3 staining (Histoscore) in breast, colorectal and ovarian cancers and 
normal tissue counterparts (Breast: normal/adjacent, n=9; cancer, n=109. Colon: normal/adjacent, 
n=14; cancer, n=107. Ovary: normal/adjacent, n=8; cancer, n=138). (d) Tukey boxplots showing DKK3 
Histoscore in non-invasive breast cancers (Stage 1&2), invasive breast-cancers (Stage 3&4) and 
normal tissue counterparts. Left graph shows all cancers irrespective of their subtype (normal, n=9; 
Stage 1&2, n=74; Stage 3&4, n=74). Middle graph shows ER-negative breast cancers (normal, n=9; 
Stage 1&2, n=40; Stage 3&4, n=40). Right graphs shows ER-positive breast cancers (normal, n=9; 
Stage 1&2, n=21; Stage 3&4, n=21). (e) Disease-free survival of breast cancer patients stratified on 
stromal DKK3 gene expression (GSE9014, ER-negative patients). (f) Images show DKK3 (green), 
vimentin (VIM; red) and DAPI (blue) staining of two representative human breast cancer tissues. 
Scale bar, 50 µm. (g) Tukey boxplot shows Dkk3 mRNA expression levels (relative to Gapdh) in 
Cancer cells (Epcam+), immune cells (Cd45+), endothelial cells (Cd31+) and fibroblasts (Pdgfra+) from 
MMTV-PyMT tumorus (n=4). (g) Graphs show correlations between the expression of DKK3 and 
ACTA2, FAP and COL1A2 in normal and cancerous stroma from mammary gland (GSE9014), 
colorectal (GSE35602) and ovarian (GSE40595) human tissues. Pearson correlation coefficient (r) is 
shown. Each dot represents z-score values from individual patients. (h) Kaplan-Meier curves of 
recurrence-free survival, disease-specific survival and progression-free survival of ER-negative breast 
cancer, colorectal cancer and ovarian cancer patients, respectively, based on DKK3 and DKK2 gene 
expression. Where indicated, individual p values are shown; alternatively the following symbols were 
used to describe statistical significance: *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001; n.s., 
non-significant. 
Figure 2. DKK3 is a HSF1 target gene associated with CAF emergence. (a) Tukey boxplots showing z-
score values of Dickkopft genes mRNA expression in murine mammary NFs and CAFs (NF, n=6; CAF, 
n=8). (b) Western blot showing protein levels of DKK3, DKK2, αSMA and tubulin in total lysates of 
two sets of murine mammary NFs and PyMT-CAFs. Levels of secreted DKK3 are also shown. (c) Venn 
diagram showing the overlap between transcription factors (TFs) known to bind the DKK3 promoter 
(left) and TFs whose perturbation modulates DKK3 expression levels (right). In red, TFs that 
negatively affect DKK3 expression; in green, TFs that positively affect DKK3 expression.. (d) Graphs 
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show Hsf1 and Dkk3 fold mRNA expression levels (relative to Rplp1) in murine PyMT-CAFs (CAF1 and 
CAF5) after transfection with control or Hsf1 siRNAs (smartpool). Bars show mean value ± SEM (n=3). 
(e) Western blots show Hsf1, Dkk3 and Gapdh expression in murine PyMT-CAFs (CAF1 and CAF5) 
after transfection with control or Hsf1 siRNAs (smartpool). (f) Graphs show correlations between 
DKK3 gene expression and HSF1 activity as measured by the expression of HSF1 gene signature (z-
score normalised) in stroma of breast, colorectal and ovarian cancers. Pearson correlation 
coefficient (r) is shown. Each dot represents z-score values from individual samples. (g) Graph shows 
binding of Hsf1 to regulatory elements in the Dkk3 gene (DKK3 P – promoter; DKK3 E – enhancer) in 
murine NF1 and CAF1. Primers targeting the bona fide Hsf1 target gene Rilpl were used as a positive 
control. Floating boxes: centre line, mean; box limits, min and max values (normalized to DNA 
amount)(n=3). Where indicated, individual p values are shown; alternatively the following symbols 
were used to describe statistical significance: *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001; 
n.s., non-significant. 
Figure 3. DKK3 is a crucial regulator of CAF functions. (a) Western blots showing DKK3 and Gapdh 
expression in murine CAF1 after transfection with control (siCtr) and 2 independent DKK3 siRNAs 
(si#2 and si#3). (b) Colour-coded grid showing fold expression of genes generally associated to CAFs 
in NF4 and wild-type CAF1 after transfection with control and 2 different DKK3 siRNAs. Colours range 
from red to blue representing respectively the lowest (zero) and highest fold activity (one). Genes 
are grouped into CAF markers, extracellular matrix (ECM) components/remodellers, secreted factors 
and transcription factors (TFs). Expression for Dkk3 is shown in a scale of green colour. (c) Histogram 
shows gel contraction by CAF1 after transfection with control (siCtr) and 2 independent DKK3 
siRNAs). Bars represent mean ± SEM (n=6). Images show representative gels remodelled. (d) Images 
show F-actin (magenta) and collagen second harmonic (SHG, green) in gels remodelled by CAF1 after 
transfection with control (siCtr) and 2 different DKK3 siRNA. Scale bar, 50 µm. (e) Histogram shows 
Young’s elastic modulus of NF1 or CAF1 cells following transfection with control (siCtr) and DKK3 
siRNA (si#sp, smart-pool). Lines represent mean ± SEM (n=34 or more individual measurements). (f) 
Western blot showing levels of DKK3 and tubulin in wild-type CAF1 (WT) and two sets of DKK3 
knock-out CAF1 clones (KO) and their recovery counterparts where DKK3 was stably re-expressed 
(KO-REC). (g) Cartoon describing the experimental set-up for the 3D co-culture system. Cancer cell 
spheroids are embedded in a collagen:Matrigel matrix containing fibroblasts and fed with media 
containing 10% FBS for 4-7 days. (h) Images show representative end-point TS1 murine breast 
cancer spheroids (red) obtained after 3D co-culture with WT, KO.9 and KO.9-REC CAFs (in blue). 
Spheroids obtained by mono-culture or by co-culture with NFs (in blue) are also shown. DAPI 
staining (green) was also used. Scale bar, 200 µm. (i) Tukey boxplots show the invasion index (3D 
invasion) and tumoral area (3D growth) measured from spheroids described in (h); n>26 individual 
spheroids out of 3 independent experiments. Where indicated, *, P < 0.05; **, P < 0.01; ***, P < 
0.001; #, P < 0.0001; n.s., non-significant. 
Figure 4. DKK3 promotes the pro-tumorigenic behaviour of CAFs in vivo. (a) Cartoon describing the 
experimental set-up used to assess the tumour-promoting potential of CAFs in vivo by subcutaneous 
co-injection of TS1 murine cancer cells and indicated CAFs. (b) Graph showing the volumes of 
tumours in syngeneic mice (FVB/n) at the indicated days post-injection. Lines represent mean ± SEM 
(n=7 or more individual tumours). (c) Survival curves for tumours as described in (b), representing 
the percentage of animals alive at the indicated time point after injection. Individual p values are 
shown. (d) Representative images showing Masson’s trichrome, fibronectin (FN), laminin and αSMA 
staining of indicated tumours at day 14 post-injection. Scale bars, 100 µm. (e) Charts show 
quantification of positive areas relative to total areas for stainings in (d). Bars indicate mean ± SEM 
(n=4 individual tumours except for WT-CAF tumours that n=5). (e) Representative images of 
intravital imaging of tumours generated by co-injection of TS1 cancer cells (red) with CAF-WT or CAF-
KO.9 CAFs (green) in CD-1 nude mice at day 20. Collagen fibres (blue) were imaged by SHG. Asterisk 
indicates areas of cancer cell invasion at the tumour border. Scale bars, 100 µm. Tukey boxplot 
shows collagen content as calculated by SHG intensity, n=24 or more fields of view at the tumour 
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border from 3 independent tumours. (f) Representative time-lapse images from intravital imaging of 
TS1 (red) and CAF-WT (green) tumours in CD-1 nude mice. Collagen fibres (blue) were imaged by 
SHG. Zoom-up areas with cancer cell movement associated to a CAF (Area 1, asterisk), cancer cell 
movement towards a CAF-enriched area (Area 1, arrow) and CAF movement (Area 2, hashtag) are 
also shown. Scale bar, 50 µm. (g) Graph showing analysis of cancer cell and CAF movement by 
intravital imaging. Bars indicate average number of moving cells per field of view ± SEM (CAF-WT, 
n=23 fields of view from 3 independent tumours; CAF-KO, n=14 fields of view from 2 independent 
tumours). For all graphs, *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001; n.s., non-significant. 
Figure 5. DKK3 potentiates β-catenin and YAP/TAZ signalling in CAFs.  (a) Graph showing GSEA of 
murine CAF1 after transfection with control siRNA (CAF-siCtr) vs CAF1 after transfection with DKK3 
siRNAs (si#2 and si#3). The graph indicates the Normalized Enrichment Score (NES) and False 
Discovery Rate (FDR) q-value (-log2) for each gene-set. In green, top differential gene-sets, including 
β-catenin and YAP/TAZ. (b) Western blot showing DKK3, non-phospho (active) β-catenin 
(Ser33/37/Thr41), β-catenin, TAZ,YAP and Gapdh levels in CAF1 after transfection with control (siCtr) 
and two independent DKK3 siRNA. (c) Images show YAP (left panels) or TAZ (right panels) localization 
(green) and DAPI staining (red) in CAF1 after transfection with control (siCtr) and two independent 
DKK3 siRNA. Scale bars, 20 µm. (d) Tukey boxplots show luciferase activity (Firefly/Renilla) indicative 
of β-catenin activation (TOPFlash reporter) or YAP/TAZ activation (4xGTIIC-lux reporter) in CAF1 after 
transfection with control (siCtr) or DKK3 (si#2&3) siRNAs; n=9 for β-catenin, n=17 for YAP/TAZ. (e) 
Left panels show total β-catenin (green), S100A4 (CAF marker, red) and DAPI (blue) staining of TS1 
tumours admixed with WT or KO.9-CAFs. Right panels show processed images showing β-catenin 
staining in CAF-positive areas. Scale bar, 100 µm. Chart shows mean β-catenin intensity in CAFs. Bars 
represent mean ± SEM (n=4 fields of view). (f) Left panels show total YAP (green), S100A4 (CAF 
marker, red) and DAPI (blue) staining of TS1 tumours admixed with WT or KO.9-CAFs. Right panels 
show processed images showing YAP staining in CAFs. Scale bar, 100 µm. Chart shows mean YAP 
intensity in CAFs. Bars represent mean ± SEM (n=19 or more fields of view). (g) Graphs show 
correlations between DKK3 gene expression and the expression of CAF-specific YAP/TAZ and β-
catenin signatures (z-score normalised) in normal and cancerous stroma from mammary gland, 
colorectal and ovarian human tissues. Pearson correlation coefficient (r) and p values are shown. (h) 
Representative Western blot showing non-phospho (active) β-catenin (Ser33/37/Thr41), β-catenin, 
TAZ, phospho-S127-YAP, YAP and tubulin in murine NF1, N4, CAF1 and CAF5. For all graphs, *, P < 
0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001; n.s., non-significant. 
Figure 6. DKK3 promotes aggressive behaviours in CAFs via YAP/TAZ.  (a) Western blots showing β-
catenin, YAP, TAZ, pY416-Src (pSRC) and pS19-MLC2 (pMLC2) and Tubulin in CAF1 following 
transfection with control (siCtr), β-catenin (siβcat; smart-pool) or YAP/TAZ (siY/T; smart-pool) 
siRNAs. (b) Tukey boxplot shows gel contraction of CAF1 transfected as in (a); n=8 gels except for 
siY/T that n=6. (c) Tukey boxplot shows invasion index (3D invasion) measured from TS1 spheroids 
obtained after 3D co-culture with CAF1 transfected as in (a)s; n>32 individual spheroids out of 3 
independent experiments. (d) Representative images of end-point TS1 (red) MOT co-culture with 
CAF1 transfected as in (a). Scale bar, 100 µm. Graph shows the area of colonies. Bars represent 
mean ± SEM (n=570 or more colonies from at least 3 independent experiments). (e) Tukey boxplot 
shows gel contraction index of CAF-WT or CAF-KO.9 stably expressing empty vector (empty) or 
constitutive active YAP mutant (YAPS5A); n=7 gels or more. (f) Representative images of end-point 
TS1 (red) MOT co-culture with CAF-KO.9 stably expressing empty vector (empty) or YAPS5A. Scale bar, 
100 µm. Tukey boxplot shows the area of colonies; n=28 or more colonies from at least 3 
independent experiments. (h) Western blot showing levels of pY416-Src (pSRC), pS19-MLC2 (pMLC2) 
and Gapdh in CAF-WT or CAF-KO.9 stably expressing empty vector (KO.9), DKK3 (KO.9-REC), or 
YAPS5A. (i) Schematic diagram showing the model integrating our findings. HSF1 in CAFs upregulates 
DKK3 which in turn potentiates YAP/TAZ and β-catenin signalling. YAP promotes actomyosin 
contractility leading to ECM remodelling and cancer cell growth and invasion. The role of β-catenin is 
still undetermined. (j) Western blots show Hsf1, non-phospho (active) β-catenin (Ser33/37/Thr41), 
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β-catenin, YAP, TAZ, pS19-MLC2 (pMLC2) and Tubulin in murine CAF1 and CAF5 after transfection 
with control (siCtr) or Hsf1 (smart-pool) siRNAs. (o) Graph shows gel contraction of CAF-WT, CAF-
KO.9-REC and CAF-KO.9-YAPS5A after transfection with control (siCtr) or Hsf1 (smart-pool) siRNAs. 
Bars represent mean ± SEM (n=3 or more). A dashed red line indicates the average contraction by 
KO.9 CAFs. For all graphs, *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001; n.s., non-significant. 
Figure 7. DKK3 potentiates canonical Wnt signalling and affects YAP/β-catenin degradation. (a) 
Western blots show β-catenin, TAZ, YAP and tubulin expression in murine WT and KO.9 CAFs after 
treatment with 100 μg mL-1 cycloheximide (CHX) for the indicated times (in min). Graph represents 
quantification of the indicated blots (normalised to tubulin) at 180 min relative to the amount at 0 
min. (b) Low and high magnification images of LRP6 (green), F-actin (red) and DAPI (blue) staining of 
murine WT, KO.9 and KO.9-REC CAFs in 1% FBS. Scale bars, 15 μm. (c) Images show YAP (green) and 
DAPI (red) staining of CAF1 after transfection with control (siCtr) and LRP5&6 siRNA (smart-pool). 
Bar, 50 µm. Graph shows quantification of nuclear relative to cytosolic fluorescent intensity (log10 
ratios) of YAP.Lines represent mean ± SEM. (d) Graph shows gel contraction index of murine WT and 
KO.9 CAFs after transfection with control (siCtr) or Lrp&6 (siLrp5/6) siRNAs. Bars represent mean ± 
SEM (n=3 or more). (e) Graph shows the area of colonies formed by TS1 MOT co-culture with WT 
and KO.9 CAFs after transfection with control (siCtr) or Lrp5&6 (siLrp5/6) siRNAs. Bars represent 
mean ± SEM (n=584 or more colonies from at least 3 independent experiments). (f)  Graph shows gel 
contraction of WT and KO CAFs cultured in 5% FBS and stimulated with vehicle or 200 ng mL-1 of 
Wnt3a or Wnt5a. Bars represent mean ± SEM (n=3). KO data are merged results of KO.2, KO.7 and 
KO.9 on triplicate (n=9). (g) Western blot showing levels of non-phospho (active) β-catenin 
(Ser33/37/Thr41), β-catenin, YAP, TAZ and Gapdh in WT and KO.9 CAFs after stimulation with vehicle 
(-) or 200 ng mL-1 of Wnt3a for 3 h. Graph represents quantification of blots indicating the fold levels 
normalised to Gapdh. (h) Images show YAP (green) and DAPI (red) staining of murine WT and KO.9 
CAFs after 16 h starvation followed by stimulation with vehicle (Starvation) or 200 ng mL-1 of Wnt3a 
for 3 h. Bar, 50 µm. Graph shows quantification of nuclear relative to cytosolic fluorescent intensity 
(log10 ratios) of YAP. Lines represent mean ± SEM. Individual p values for different comparisons are 
shown. For all graphs, *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001; n.s., non-significant. 
Figure 8. DKK3 regulates the balance between LRP6 and Kremen and affects YAP/TAZ signalling. 
(a) Western blots show anti-Flag co-immune-precipitation of LRP6 and Kremen1 in human BC-CAFs 
(TB147) expressing Flag-DKK3 or empty vector (null).(b) Images show DKK3 (green), Kremen1 (red) 
and DAPI (blue) staining of human BC-CAF TB165 after transfection with control (siCtr) and DKK3 
siRNA (smart-pool). Scale bars, 15 µm. (c) Images show LRP6 (green), Kremen1 (red) and DAPI (blue) 
staining of human BC-CAF TB165 transfected as in (b). Scale bars, 15 µm. (d) Western blots show 
LRP6, Kremen1, Kremen2, DKK3 and Gapdh expression in WT and KO.9 CAFs. (e) Western blots show 
LRP6, Kremen1 and tubulin expression in indicated CAFs after treatment with 100 μg mL-1 
cyclohexamide (CHX) at different times (in min). Graph represents quantification of the indicated 
blots (normalised to tubulin) at 180 min relative to the amount at 0 min. (f) Western blots show non-
phospho (active) β-catenin (Ser33/37/Thr41), TAZ, Kremen1 and Tubulin CAF-KO.9 after transfection 
with control (siCtr) and Kremen1&2 siRNA (smart-pool). (g) Graph shows gel contraction of KO.9 
CAFs after transfection with control (siCtr), Kremen1 (siKr1), Kremen2 (siKr2) or Kremen1&2 
(siKr1&2) siRNAs (smartpool). Bars represent mean ± SEM (n=4 or more individual gels). (h) Graph 
shows the invasion index of TS1 spheroids after 3D co-culture with KO.9 CAFs transfected as in (f)s. 
Bars represent mean ± SEM (n=11 or more individual spheroids, 2 independent experiments). (i) 
Graph shows the tumoral area of TS1 MOT co-culture with KO.9 CAFs transfected as in (f). Bars 
represent mean ± SEM (n=348 or more colonies, at least 3 independent experiments). (j) Images 
show LRP6 (green), GM1 (red) and DAPI (blue) staining of indicated CAFs. Cells were fixed and 
subjected to staining without permeabilisation. Scale bar, 15 μm. (k) Images show YAP (green) and 
DAPI (red) staining of KO.9 CAFs transfected as in (f).. Bar, 30 µm. Graph shows quantification of 
nuclear relative to cytosolic fluorescent intensity (log10 ratios) of YAP Lines represent mean ± SEM. 
For all graphs, *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001; n.s., non-significant. 
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Figure 9. Model depicting the proposed mechanism of DKK3-mediated regulation of YAP/TAZ and 
β-catenin in CAFs. On CAFs, DKK3 destabilises Wnt negative regulator Kremen leading to increased 
LRP6 membrane localisation, which in turn stabilises YAP/TAZ and β-catenin levels via canonical 
Wnt. Whereas β-catenin signalling is dispensable for CAFs to remodel the ECM and promote cancer 
cell growth and invasion, DKK3-driven YAP activation is required to induce a tumour-promoting 
phenotype. Absence of DKK3 in DKK3-null CAFs and NFs is associated with decreased YAP/TAZ and β-
catenin activity. In CAFs, loss of DKK3 leads to concomitant upregulation of Kremen, LRP6 
inactivation and YAP/TAZ and β-catenin destabilization. In this scenario, depletion of Kremen1/2 is 
able to rescue LRP6 membrane localization and YAP/TAZ and β-catenin activity.  
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Supplementary Figure 1.  DKK3 expression in the tumour stroma. (a) Table showing the differential levels of expression of Dickkopft 
genes (DKK3, DKK1, DKK2, DKK4 and DKKL1) between normal and cancerous stroma in different types of tumours (breast, ovary, colon, 
aesophagus, oral squamous cell carcinoma, lung and pancreas). Public datasets used to extract the information and the specific probe 
are indicated. Additional information includes whether genes are upregulated/downregulated in cancer stroma; colours range from 
dark green (significantly upregulated), light green (non-significantly upregulated), light red (non-significantly downregulated) and dark 
red (significantly upregulated).  p values for each probe and dataset are provided; colours range from orange (highly significant), yellow 
(significant) to white (non-significant). (b) Tukey boxplots showing quantification of DKK3 staining (Histoscore) in non-invasive breast 
cancers (Stage 1&2), invasive breast-cancers (Stage 3&4) and normal tissue counterparts. Left graph shows triple-negative breast 
cancers (TNBC) and right graph shows HER2-positive breast cancers (TNBC: normal, n=9; Stage 1&2, n=10; Stage 3&4, n=10. HER2-
positive: normal, n=9; Stage 1&2, n=30; Stage 3&4, n=30). (c) Diagram showing the FACS gating strategy to isolate different cell 
populations from MMTV-PyMT murine mammary tumours. (d) Expression of indicated genes (relative to Gapdh) in different cell 
populations isolated from MMTV-PyMT mammary tumours: Cancer cells (Epcam+), immune cells (Cd45+), endothelial cells (Cd31+) and 
fibroblasts (Pdgfra+). Expression of Dkk2 is also shown. Floating boxes: centre line, mean; box limits, min and max values (n=4 individual 
tumours for all graphs, except Ck18, n=3; and Pdgfra, Fap and Fn1, n=5). (e) Tukey boxplot showing DKK3 and DKK2 mRNA expression 
levels (z-score) in FACS sorted cell populations isolated from human colorectal tumours: Cancer cells (Epcam+), immune cells (CD45+), 
endothelial cells (CD31+) and fibroblasts (FAP+). From GSE39396; (n=6 individual tumours).  
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Supplementary Figure 2. DKK3 expression in human CAFs. (a) (Left and middle) Tukey boxplots showing z-score values of DKK3 mRNA 
expression in NFs and CAFs from human breast (left, extracted from GSE20086; n=6) and human colon (middle, extracted from 
GSE70468; n=7). Right graph shows z-score values of DKK3 mRNA expression in matched human ovarian NFs and CAFs (extracted from 
GSE35250, n=3). p values are shown. (b) Western blot showing levels of DKK3, DKK2, DKK1, αSMA, FAP, S100A4 and tubulin in total 
lysates of human breast, colon and ovarian cancer NFs and CAFs. Where indicated, expression levels of cancer-type-matched cancer 
lines are also shown. (c) (Left panels) Images show DKK3 (green) and DAPI (blue) staining of human breast CAFs (13T), rectal CAFs 
(RC11) and colon CAFs (CAF25). (Right panels) Images show same cells counterstained for αSMA (red) and DAPI (blue). Scale bars, 150 
µm. (d) Images show DKK3 (green) and FAP (red) staining of human colon CAFs (RC11). Upper panel shows merged image. Scale bar, 
150 µm. (e) Charts show Dkk3 mRNA expression (shown as z-score) in wild-type (HSF1wt) and Hsf1-null (HSF1-/-) MEFs in two 
independent datasets (GSE3074 and GSE56252). Bars represent mean value ± SD. 
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Supplementary Figure 3. DKK3 modulates CAF functions. (a) Graph shows gel contraction by CAF5 after transfection with control 
(siCtr) and DKK3 (si#2&3) siRNAs. Bars represent mean ± SEM (n=5 individual gels). (b) Diagram showing the targeting sequence (red) 
for endogenous Dkk3 CRISPR/CAS9 knock-out in murine wild-type CAFs. Underneath, sequences of the same Dkk3 locus on KO.9 and 
KO.2 CAFs, showing the targeted deletion of two single bases. (c) Images show gels remodelled by WT and KO.9 CAFs, with a dashed 
white line delineating the final gel area. Histogram shows gel contraction by the indicated CAF lines. Gel remodelling activity of a CAF1 
DKK3-positive clone (WT.9) is also shown. Bars represent mean ± SEM (6<n<10 individual gels). (d) Histogram shows fibre content (i.e. 
reflectance intensity) in gels remodelled by WT and KO.9 CAFs. Bars represent mean ± SEM (n=5). (e) Cartoon describing the 
experimental set-up for the Matrigel on top (MOT) co-culture system. Cancer cells (green) alone or mixed with fibroblasts (red) are 
seeded on top of a thin layer of Matrigel (pink) and fed with media containing 10% FBS and 2% Matrigel (orange). (f) Representative 
images of end-point TS1 murine breast cancer cells (red) obtained after MOT co-culture with WT, KO.9 and KO.9-REC CAFs (not shown). 
Scale bar, 250 µm. Graph shows the tumoral area as measured from the size of colonies. Bars represent mean ± SEM (n>28 individual 
colonies out of 3 independent experiments).  
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Supplementary Figure 4. DKK3 promotes pro-tumorigenic functions in human CAFs. (a) Western blot showing levels of DKK3 and 
tubulin in human breast CAFs (TB165-BC-CAFs and TB147-BC-CAFs), colorectal CAFs (RC11-CR-CAFs and CAF25-CR-CAF) and ovarian 
CAFs (EOC.TIL.04-OV-CAFs) stably expressing control (shCtr) and DKK3 (shDKK3) shRNAs. (b) Histogram showing gel contraction by the 
indicated human CAF lines (breast, green bars; colorectal, red bars; ovarian, blue bars) stably expressing control (dark coloured bars) or 
DKK3 (light coloured bars) shRNAs. Bars represent mean ± SEM (n=4 or more individual gels out of at least 3 independent experiments). 
(c) Images show representative end-point spheroids of breast cancer (BT20), colon cancer (HCT116) and ovarian cancer (SKOV3) cells 
(red) obtained after 3D co-culture with tumour-matched CAFs (TB165, RC11 and EOC.TIL.04, respectively) stably expressing control or 
DKK3 shRNA (blue). Spheroids obtained by mono-culture (i.e. no fibroblasts added) are also shown. DAPI staining (green) was also used. 
Scale bar, 200 µm. (d) Tukey boxplots show the invasion index (3D invasion) measured from spheroids described in (i); n=15 or more 
spheroids out of at least 3 independent experiments. 
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Supplementary Figure 5. Ectopic expression of DKK3 in NFs induces an activated phenotype. (a) Western blot showing levels of DKK3 
and Tubulin in murine NF after stable ectopic expression of DKK3 or empty vector. (b) Graph showing gel contraction at 48 and 96 h of 
NF-empty and NF-DKK3. Bars represent mean ± SEM (n=5 individual gels, 2 individual experiments). (c) Images show representative 
end-point TS1 spheroids (red) after 3D co-culture with NF-empty and NF-DKK3 (blue). DAPI staining (green) was also used. Scale bar, 
200 µm. Tukey boxplot shows the invasion index; n>25 individual spheroids out of 3 independent experiments. (d) Histograms showing 
proliferation index (Left) and migration in wound healing assays (Right) of TS1 cells when cultured in normal media (vehicle), media 
containing 100 ng mL-1 recombinant DKK3 (rDKK3) or conditioned media (CM) obtained from WT, KO.9 and KO.9-REC CAFs. Bars 
represent mean ± SEM (proliferation: n=16 replicates, 4 independent repeats, migration, n=8 replicates, 4 independent repeats). (e) 
Histograms showing proliferation index (Left) and migration in wound healing assays (Right) of TS1 cells when cultured in conditioned 
media from CAF1 (with detectable secreted DKK3) or CAF5 (no detectable secreted DKK3, See Figure 1i). As indicated, cells were 
cultured in the presence of 1 µg mL-1 of a blocking antibody against DKK3 or with isotype control antibody. Bars represent mean ± SEM 
(proliferation: n=8 replicates, 4 independent repeats; migration: n=4 independent repeats). (f) Effect of recombinant DKK3 and DKK3-
containing medium on CAF-KO.9. Graph shows the gel contraction index of CAF-KO.9 when cultured in normal media (vehicle), media 
containing 100 ng mL-1 recombinant DKK3 (rDKK3) or conditioned media (CM) obtained from WT or KO.9 CAFs. Bars represent mean ± 
SEM (3<n<10). (g) Graph showing the volumes of tumours generated by co-injection of TS1 cells with NF-empty or NF-DKK3 in 
syngeneic mice (FVB/n) at the indicated days post-injection. Lines represent mean ± SEM (n=8 for NF-empty; n=7 for NF-DKK3). For all 
graphs, *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001; n.s., non-significant. 
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Supplementary Figure 8. DKK3 regulation of YAP/TAZ is independent of the Hippo pathway.  (a) GSEA plots show the enrichment of 
β-catenin and YAP/TAZ target genes in CAF-siCtr vs CAF-siDKK3. Nominal Enrichment Score (NES), False discovery rate (FDR) q-value 
and standard p-value are shown for both plots. (b) Western blot showing non-phospho (active) β-catenin (Ser33/37/Thr41), TAZ, DKK3 
and Tubulin levels in KO.2, KO.2-REC, KO.9, KO.9-REC CAFs. Graph represents quantification of the blots showing the amount of active-
β-catenin and TAZ (normalised to tubulin) in KO-REC relative to KO CAFs (n=2). (c) Graphs show quantification of nuclear relative to 
cytosolic fluorescent intensity (log10 ratios) of YAP or TAZ in murine WT, KO.9 and KO.9-REC CAFs Each dot represents a single cell from 
3 independent experiments. Lines represent mean ± SEM. (d) Images show total β-catenin (green), active-β-catenin (red), and DAPI 
(blue) staining of human colorectal RC11 CAFs after transfection with control (siCtr) or DKK3 siRNA (smart-pool). Scale bar, 100 µm. (e) 
Images shown YAP (green) and TAZ (red) localization and DAPI staining (blue) in human colorectal RC11 CAFs after transfection with 
control (siCtr) or DKK3 siRNA (smart-pool). Scale bars, 50 µm. (f) Graphs show normalized β-catenin, YAP and TAZ activation in human 
CAFs (TB165, breast cancer, green bars; RC11, rectal, red bars; EOC.TIL.04, ovarian, blue bars) after transfection with control (siCtr, dark 
colour) or DKK3 siRNA (smart-pool; siDKK3, light colour). Bars represent mean ± SEM (n=19 or more fields of view for β-catenin; n=298 
or more single cells for YAP and TAZ analysis). (g) Representative Western blots showing non-phospho (active) β-catenin 
(Ser33/37/Thr41), YAP, TAZ, DKK3 and Tubulin in human mammary NFs (GS1 and GS6) after stable ectopic expression of empty vector 
or DKK3. 
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Supplementary Figure 9. Uncropped immunoblot images. Uncropped immunoblot images corresponding to the indicated Main 
Figures. Cropped images are delineated by a red box. Molecular size markers are in kDa.  
NAME SIZE ES NES NOM p-val FDR q-val LEADING EDGE 
CAF_BCAT_ALL_UP 171 0.5100316 2.3684409 0 0 tags=36%, list=8%, signal=39% 
CAF_YAPTAZ_ALL_UP 1087 0.39539856 2.0733216 0 0.00100357 tags=40%, list=24%, signal=49% 
DASATINIB_DN 208 0.41236395 1.9052991 0 0.00597356 tags=39%, list=25%, signal=52% 
UP_IN_STIFF_MATRIX_AND_PROLIF 40 0.5269615 1.8663244 0 0.00904752 tags=58%, list=32%, signal=84% 
BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_UP 29 0.5718424 1.8431051 0.00308642 0.01046525 tags=34%, list=11%, signal=39% 
INTERFERON_IN_COCULTURE 21 0.59700376 1.8194805 0 0.0128522 tags=57%, list=10%, signal=63% 
DASATINIB_NLF_VS_LCAF_DN 59 0.46670222 1.7978599 0 0.01549632 tags=49%, list=25%, signal=65% 
CHANG_CYCLING_GENES 45 0.4761665 1.7479564 0.00342466 0.02394448 tags=53%, list=32%, signal=79% 
CHEMOKINES 46 0.4477555 1.6653389 0.0131579 0.04840102 tags=24%, list=8%, signal=26% 
SRC_GENES 40 0.46124756 1.6430713 0.01269841 0.05564842 tags=23%, list=12%, signal=26% 
BERENJENO_TRANSFORMED_BY_RHOA_UP 516 0.32271415 1.6378736 0 0.05520763 tags=43%, list=30%, signal=59% 
OVEREXPRESSED_G3_TO_G1 60 0.41245773 1.5733459 0.0203252 0.08515406 tags=35%, list=24%, signal=46% 
BIOCARTA_WNT_PATHWAY 24 0.49468163 1.5402899 0.02686567 0.10252612 tags=25%, list=14%, signal=29% 
DASATINIB_AND_QUIESCENCE_DN_ 13 0.5902231 1.5396316 0.05865922 0.0985544 tags=62%, list=28%, signal=86% 
IL5_UP 120 0.34324872 1.479517 0 0.13877364 tags=31%, list=20%, signal=38% 
UP_IN_CAFS_FROM_COLON_CANCER_VS_OTHER_CELLS 189 0.31326473 1.4692802 0 0.1438278 tags=22%, list=15%, signal=26% 
UP_IN_TUMOUR_VASCULATURE 22 0.47055393 1.4622253 0.0497076 0.14508827 tags=45%, list=20%, signal=57% 
WILLERT_WNT_SIGNALING 19 0.4887554 1.4513843 0.0480226 0.14925931 tags=21%, list=5%, signal=22% 
TPX2_METAGENE_VALIDATION_MSIGDB_CELLCYCLE 60 0.36732814 1.437243 0.02631579 0.15695032 tags=50%, list=32%, signal=73% 
SANZ_ROCK_RESPONSIVE_GENES_TOP_600 159 0.31809756 1.4180127 0.00606061 0.16263932 tags=24%, list=14%, signal=28% 
EGFR1_UP 86 0.34374973 1.395742 0.03167421 0.17869161 tags=27%, list=15%, signal=31% 
SANZ_ROCK_RESPONSIVE_GENES_TOP_200 118 0.316888 1.382767 0.02051282 0.1856779 tags=20%, list=13%, signal=23% 
B_CATENIN_GENES 42 0.38845336 1.3727274 0.07692308 0.19088629 tags=33%, list=21%, signal=42% 
UP_IN_OVARIAN_CANCER_STROMA 181 0.2949167 1.3692465 0 0.18863927 tags=28%, list=22%, signal=36% 
SECRETED_IN_PTEN_NULL_ETS2_TARGETS 17 0.48181775 1.3652046 0.1160221 0.18745367 tags=12%, list=6%, signal=13% 
SECRETED_IN_PTEN_NULL_MIR_CONTROL_ONLY 30 0.4039811 1.3317623 0.09567902 0.2186328 tags=13%, list=7%, signal=14% 
DASATINIB_CSR_DN 20 0.44028944 1.3092022 0.10447761 0.24180101 tags=50%, list=26%, signal=67% 
WNT_SIGNATURE 58 0.33531976 1.2885729 0.07539683 0.2614431 tags=22%, list=9%, signal=24% 
TSAO_FAK_RESPONSIVE_GENES_TOP_100 75 0.31272438 1.2758709 0.04705882 0.27267656 tags=29%, list=17%, signal=35% 
WNT3A_DN_HLF 9 0.5346626 1.2734178 0.17985612 0.26954615 tags=33%, list=13%, signal=38% 
ESR1_METAGENE_VALIDATION_MSIGDB_FRASOR_ER_UP 28 0.38853478 1.2609129 0.1574074 0.28064287 tags=21%, list=6%, signal=23% 
IL1_UP 74 0.31007522 1.2485667 0.07287449 0.29375798 tags=23%, list=8%, signal=25% 
WNT3A_2_DN 27 0.3811855 1.2483094 0.1411043 0.28734648 tags=26%, list=10%, signal=29% 
CHANG_CORE_SERUM_RESPONSE_UP 61 0.31913802 1.2321556 0.11857708 0.3028827 tags=49%, list=33%, signal=73% 
TSAO_FAK_RESPONSIVE_GENES_TOP_200 143 0.2776171 1.2282292 0.06060606 0.30267477 tags=32%, list=19%, signal=39% 
EMT_SIGNATURE 59 0.3225245 1.2093763 0.16544117 0.32592374 tags=34%, list=20%, signal=42% 
FINAK_BREAST_CANCER_SDPP_SIGNATURE 22 0.37436864 1.1880885 0.1934605 0.35692298 tags=23%, list=6%, signal=24% 
RAS_GENES 164 0.25897092 1.1806686 0.05517241 0.36246186 tags=16%, list=12%, signal=18% 
BECK_2008_DTF_SHORT 60 0.30819032 1.1794986 0.17037037 0.3571626 tags=27%, list=21%, signal=34% 
SANZ_ROCK_RESPONSIVE_GENES_TOP_100 81 0.28906658 1.1793437 0.14893617 0.35046917 tags=20%, list=13%, signal=23% 
REACTOME_SIGNALING_BY_WNT 56 0.31364837 1.1728323 0.16731517 0.3551215 tags=52%, list=40%, signal=86% 
TNFA_NFKB_UP 109 0.27112076 1.1702441 0.12834224 0.35295495 tags=29%, list=15%, signal=34% 
BECK_2008_DTF_LONG 153 0.2581587 1.1609442 0.09202454 0.3629104 tags=16%, list=11%, signal=18% 
WNT_DN 9 0.49414393 1.1510755 0.3073048 0.37384212 tags=56%, list=14%, signal=65% 
DTFD 31 0.3373959 1.14089 0.25787964 0.38507834 tags=26%, list=13%, signal=30% 
UP_IN_NORMAL_VASCULATURE 42 0.30997026 1.1207839 0.22556391 0.4173743 tags=14%, list=10%, signal=16% 
UP_IN_CAF 161 0.24336624 1.114415 0.14634146 0.4233718 tags=37%, list=25%, signal=48% 
HYPOXIA2_UP 13 0.41652825 1.0884635 0.34770888 0.47211733 tags=38%, list=16%, signal=46% 
KEGG_WNT_SIGNALING_PATHWAY 143 0.2419189 1.087065 0.25748503 0.467269 tags=20%, list=14%, signal=23% 
IL2_UP 432 0.21722798 1.0866679 0.11666667 0.46057093 tags=20%, list=15%, signal=22% 
WNT_GENES 18 0.36082 1.0485356 0.38055557 0.5409049 tags=17%, list=3%, signal=17% 
UP_IN_COLON_CANCER_STROMA 185 0.22737516 1.046461 0.27083334 0.537197 tags=16%, list=11%, signal=17% 
E2F3_GENES 140 0.2366722 1.0458014 0.3105263 0.5303604 tags=21%, list=16%, signal=25% 
BASAKI_YBX1_TARGETS_UP 257 0.21614937 1.0435109 0.28723404 0.52801985 tags=30%, list=27%, signal=41% 
TGFB_TARGET_GENES 75 0.25324655 1.0200565 0.425 0.5786391 tags=12%, list=8%, signal=13% 
IL9_UP 25 0.32966632 1.017685 0.44207317 0.5757127 tags=16%, list=3%, signal=16% 
SRFMALB 25 0.31936678 1.012284 0.42944786 0.57971025 tags=24%, list=20%, signal=30% 
SFT 101 0.23679604 0.99852526 0.45454547 0.60697395 tags=37%, list=22%, signal=47% 
STROMAL_SIGNATURE_RESISTANCE_TO_CHEMOTHERAPY 44 0.27804467 0.9945592 0.4602649 0.6083814 tags=16%, list=11%, signal=18% 
CD83_METAGENE_VALIDATION_MSIGDB_CD40_PATHWAYS 12 0.36996454 0.97242063 0.45576409 0.6577655 tags=25%, list=14%, signal=29% 
YAP 60 0.24911 0.96994513 0.50763357 0.65552783 tags=25%, list=14%, signal=29% 
BERENJENO_TRANSFORMED_BY_RHOA_FOREVER_DN 31 0.28467947 0.95439863 0.5379939 0.68731874 tags=42%, list=23%, signal=54% 
SECRETOME_SIGNATURE 37 0.2717667 0.95388365 0.50859106 0.67934996 tags=11%, list=7%, signal=12% 
GZMA_METAGENE_VALIDATION_MSIGDB_TCRA_PATHWAY 9 0.39855123 0.945988 0.55949366 0.69006723 tags=44%, list=13%, signal=51% 
STAT3_EXPRESSION_SIGNATURE 10 0.3754142 0.9113359 0.6065163 0.76580864 tags=20%, list=5%, signal=21% 
FABP4_METAGENE_VALIDATION_MSIGDB_FATTYACID_DEGRADATI
ON 
22 0.29789293 0.90943056 0.5862069 0.76000625 tags=36%, list=22%, signal=47% 
HYPOXIA2_DN 6 0.42478168 0.90356815 0.5704057 0.7633641 tags=67%, list=18%, signal=81% 
BREAST_STROMA 9 0.38067257 0.9009057 0.60097325 0.75971454 tags=11%, list=0%, signal=11% 
WNT3A_UP_HLF 60 0.23006903 0.8817408 0.6967509 0.7913671 tags=13%, list=6%, signal=14% 
BERENJENO_TRANSFORMED_BY_RHOA_FOREVER_UP 18 0.3065489 0.88030595 0.6426593 0.7842404 tags=22%, list=13%, signal=26% 
YAP_TAZ_COMMON 544 0.16726863 0.8379164 1 0.8580315 tags=24%, list=21%, signal=29% 
BREAST_EPITHELIUM 9 0.35247335 0.83541495 0.6580189 0.8518681 tags=22%, list=6%, signal=24% 
IGS_INVASIVENESS_GENE_SIGNATURE 113 0.18892017 0.8256004 0.8995215 0.8581976 tags=39%, list=28%, signal=54% 
REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY 13 0.29949048 0.7658761 0.7622549 0.9369401 tags=23%, list=15%, signal=27% 
IL5_DN 8 0.3259288 0.7588544 0.77057356 0.9337192 tags=25%, list=12%, signal=28% 
IGF1 252 0.15659869 0.7533783 1 0.9299305 tags=23%, list=25%, signal=30% 
MX_METAGENE_VALIDATION_MSIGDBIFNPATHWAY 8 0.3296809 0.7530671 0.7762238 0.9194759 tags=13%, list=5%, signal=13% 
NGUYEN_NOTCH1_TARGETS_UP 21 0.2351851 0.71200347 0.8785311 0.9475462 tags=33%, list=26%, signal=45% 
SECRETED_IN_PTEN_NULL_MIR320_AND_CONTROL 53 0.17200081 0.6451299 0.99298245 0.97928137 tags=19%, list=19%, signal=23% 
SECRETOME_SIGNATURE_ETS2_TARGETS 13 0.18794869 0.5035284 0.98039216 1 tags=15%, list=18%, signal=19% 
SECRETED_IN_PTEN_NULL_MIR320_ONLY 16 0.17385834 0.49005717 0.9895013 0.9957234 tags=38%, list=32%, signal=55% 
TAZ_INDUCED_GENES 1462 0.19637047     1 tags=30%, list=26%, signal=37% 
Ferrari et al. Supplementary Information. Supplementary Table 1. 
NAME SIZE ES NES NOM p-val FDR q-val LEADING EDGE 
CAF_BCAT_ALL_DN 203 -0.6452891 -2.4904265 0 0 tags=61%, list=14%, signal=70% 
DASATINIB_CSR_UP 16 -0.6712642 -1.7059835 0.00802568 0.01617807 tags=56%, list=23%, signal=73% 
HGF_DN 18 -0.6019741 -1.6121591 0.01926164 0.04520309 tags=44%, list=14%, signal=52% 
DASATINIB_UP 141 -0.4199701 -1.5733957 0.00120337 0.06164124 tags=39%, list=22%, signal=49% 
CAF_YAPTAZ_ALL_DN 879 -0.3575035 -1.4962401 0 0.11768349 tags=33%, list=19%, signal=39% 
DN_IN_STROMA_WHEN_METS 9 -0.6116958 -1.3194784 0.12798634 0.43185088 tags=33%, list=10%, signal=37% 
SRFMALA 120 -0.3623683 -1.3185855 0.05882353 0.40576732 tags=29%, list=23%, signal=38% 
L1601P_GENES_UP_NOTCH_UP 123 -0.3507254 -1.2888318 0.06976745 0.46668872 tags=28%, list=14%, signal=33% 
CSF1R_CORE_SHORT 97 -0.3534102 -1.2784195 0.07850708 0.47026992 tags=35%, list=20%, signal=44% 
WNT_UP 33 -0.4312946 -1.2775955 0.15827338 0.42270362 tags=36%, list=16%, signal=43% 
TGFB 182 -0.3267436 -1.2525476 0.07339449 0.47281578 tags=26%, list=20%, signal=33% 
UP_IN_STROMA_WHEN_METS 38 -0.4049588 -1.2514036 0.15417255 0.45366746 tags=21%, list=11%, signal=24% 
CLCA2_METAGENE_VALIDATION_MSIGDB_NELSON_ANDROGEN_UP 53 -0.3850158 -1.2508042 0.16576087 0.434756 tags=45%, list=30%, signal=65% 
CSF1R_CORE_LONG 182 -0.3243769 -1.2391858 0.09132948 0.4458404 tags=31%, list=20%, signal=38% 
IL4_UP 166 -0.3151875 -1.206133 0.11729858 0.5251247 tags=25%, list=16%, signal=29% 
NICD_GENES_UP_NOTCH_UP 675 -0.2810855 -1.1778785 0.04786151 0.59500396 tags=21%, list=16%, signal=24% 
HYPOXIA 48 -0.3670543 -1.1721606 0.23021583 0.59306717 tags=27%, list=20%, signal=34% 
UP_IN_NF 109 -0.3112574 -1.1292586 0.23321123 0.725402 tags=34%, list=24%, signal=44% 
IL6_UP 13 -0.462529 -1.1264745 0.31061807 0.7096828 tags=38%, list=23%, signal=50% 
DASATINIB_AND_QUIESCENCE_UP 19 -0.4189483 -1.1171187 0.3114504 0.72052497 tags=32%, list=18%, signal=38% 
TEAD_DEPENDENT_YAP_TARGET_GENES_COMMON_BETWEEN_YA
P_AND_TAZ 
31 -0.379337 -1.1097721 0.32900432 0.7234895 tags=42%, list=28%, signal=58% 
YAP_TAZ_CONSERVED 56 -0.3360014 -1.1042212 0.29781422 0.72082245 tags=25%, list=20%, signal=31% 
NOTCH_UP 17 -0.4314299 -1.0987349 0.3423138 0.7188801 tags=18%, list=4%, signal=18% 
MAMMOSPHERE 24 -0.3941557 -1.075229 0.3897059 0.78576946 tags=33%, list=19%, signal=41% 
UP_IN_BREAST_CANCER_STROMA_FINAK 167 -0.2836145 -1.0698419 0.322807 0.7833638 tags=22%, list=13%, signal=25% 
BERENJENO_TRANSFORMED_BY_RHOA_DN 382 -0.2570463 -1.0536366 0.34632036 0.82469773 tags=37%, list=30%, signal=51% 
TGFB_PADUA 130 -0.2792285 -1.0374708 0.37875 0.8667753 tags=25%, list=25%, signal=34% 
UP_IN_BREAST_CANCER_STROMA_KARNOUB 155 -0.2685953 -1.0280514 0.41970804 0.8799523 tags=30%, list=23%, signal=38% 
CHANG_CORE_SERUM_RESPONSE_DN 27 -0.3593718 -1.0273616 0.41420117 0.8592859 tags=41%, list=28%, signal=57% 
UP_IN_YAP_LIVER 709 -0.2465016 -1.0260534 0.41598362 0.84172153 tags=20%, list=20%, signal=24% 
BERENJENO_TRANSFORMED_BY_RHOA_REVERSIBLY_UP 8 -0.4867267 -1.0144619 0.47440273 0.86324346 tags=25%, list=9%, signal=27% 
UP_IN_PYMT_CAFS_VS_NF 190 -0.2611817 -1.0133586 0.44 0.846394 tags=19%, list=17%, signal=23% 
WNT3A_2_UP 30 -0.3496065 -1.0106475 0.45760235 0.8358374 tags=37%, list=26%, signal=50% 
HGF_UP 56 -0.3084348 -1.0050954 0.445215 0.8350834 tags=14%, list=9%, signal=16% 
TEAD_DEPENDENT_YAP_TARGET_GENES_UNIQUE_TO_YAP 21 -0.3665148 -0.9982209 0.46270928 0.84094113 tags=29%, list=23%, signal=37% 
DOWN_IN_STIFF_MATRIX 52 -0.3020471 -0.978011 0.4979592 0.8911025 tags=27%, list=22%, signal=35% 
YAPTAZ 66 -0.2920919 -0.9749934 0.5045632 0.8817606 tags=21%, list=20%, signal=26% 
TSAO_FAK_RESPONSIVE_GENES__TOP_600 385 -0.2404036 -0.9706699 0.5729387 0.8767035 tags=16%, list=12%, signal=18% 
DASATINIB_NLF_VS_LCAF_UP 26 -0.3404789 -0.968454 0.5263158 0.8656578 tags=42%, list=27%, signal=58% 
ADM_METAGENE_VALIDATION_MSIGDB_HIFPATHWAY 12 -0.4106454 -0.9651203 0.516184 0.8585951 tags=8%, list=1%, signal=8% 
NFKB 159 -0.2536896 -0.9641835 0.5400239 0.84455043 tags=25%, list=19%, signal=30% 
VANTVEER_BREAST_CANCER_POOR_PROGNOSIS 41 -0.3101444 -0.9641796 0.5227606 0.82799065 tags=12%, list=6%, signal=13% 
NOTCH_SIGNALING_PATHWAY 12 -0.4064188 -0.9637584 0.5152 0.8134396 tags=67%, list=37%, signal=105% 
PDGF 13 -0.3970734 -0.959429 0.5223421 0.8110043 tags=46%, list=35%, signal=71% 
NICD_GENES_DOWN_NOTCH_DOWN 841 -0.2270055 -0.9567062 0.64658636 0.80407107 tags=21%, list=19%, signal=25% 
DCN_METAGENE_VALIDATION_MSIGDB_TGFB_SIGNALLING_PATHW
AY 
47 -0.2995402 -0.9546415 0.5396384 0.7949489 tags=34%, list=26%, signal=46% 
WNT_TARGET_GENES 92 -0.2616469 -0.9226178 0.625323 0.8675414 tags=22%, list=15%, signal=25% 
RANKL_UP 49 -0.2823421 -0.9074553 0.6181047 0.8911211 tags=18%, list=12%, signal=21% 
BASAKI_YBX1_TARGETS_DN 313 -0.2196964 -0.8839042 0.7758433 0.9342578 tags=22%, list=20%, signal=28% 
MYC_GENES 110 -0.2431145 -0.8727415 0.734414 0.94532514 tags=15%, list=15%, signal=18% 
IL3_UP 16 -0.3386577 -0.8627421 0.65217394 0.95195925 tags=44%, list=31%, signal=63% 
L1601P_GENES_DOWN_NOTCH_DOWN 37 -0.2743906 -0.8486379 0.6896552 0.96678096 tags=16%, list=8%, signal=18% 
TGFB_ADORNO 136 -0.2258532 -0.8369581 0.8171913 0.9754914 tags=25%, list=21%, signal=31% 
IL1_DN 33 -0.2794975 -0.8365638 0.7349927 0.9608314 tags=24%, list=16%, signal=29% 
HOSHIDA_LIVER_CANCER_SUBCLASS_S1 220 -0.2094288 -0.8198768 0.87093157 0.9768792 tags=15%, list=16%, signal=18% 
REACTOME_SIGNALING_BY_NOTCH 16 -0.3188872 -0.8068203 0.7464342 0.98555046 tags=19%, list=14%, signal=22% 
IL2_DN 243 -0.2042531 -0.8064457 0.9065315 0.9712625 tags=14%, list=15%, signal=17% 
YAP_INDUCED_GENES 997 -0.1900561 -0.7990856 0.9899295 0.96904176 tags=21%, list=25%, signal=26% 
IL4_DN 71 -0.2337412 -0.7967912 0.8425197 0.95845425 tags=25%, list=20%, signal=32% 
RANKL_DN 15 -0.3096829 -0.7855121 0.7832512 0.9613825 tags=27%, list=16%, signal=32% 
YAP_UP 976 -0.1844274 -0.7763023 0.9949495 0.96031094 tags=20%, list=25%, signal=26% 
EGFR1_DN 42 -0.2505257 -0.7663638 0.84791964 0.9591901 tags=33%, list=30%, signal=48% 
NOTCH_DN 5 -0.4084545 -0.7524144 0.7775832 0.96273273 tags=40%, list=14%, signal=47% 
BERENJENO_TRANSFORMED_BY_RHOA_REVERSIBLY_DN 28 -0.2429434 -0.7022601 0.89301634 0.997088 tags=14%, list=20%, signal=18% 
TNFA_NFKB_DN 7 -0.3372279 -0.6904588 0.85045046 0.9918127 tags=14%, list=3%, signal=15% 
IL7_UP 20 -0.2539844 -0.6809104 0.8844444 0.98512787 tags=30%, list=24%, signal=40% 
BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN 48 -0.2118798 -0.6757336 0.941094 0.9754793 tags=29%, list=28%, signal=40% 
UP_IN_STIFF_MATRIX 42 -0.2114296 -0.6589775 0.9431818 0.97163904 tags=24%, list=28%, signal=33% 
NGUYEN_NOTCH1_TARGETS_DN 63 -0.1935534 -0.6520087 0.97705805 0.9626167 tags=29%, list=29%, signal=40% 
KEGG_NOTCH_SIGNALING_PATHWAY 46 -0.1897905 -0.6022859 0.97910863 0.96780443 tags=46%, list=40%, signal=76% 
Supplementary Table 1. GSEA report. Table describing the GSEA analysis including gene set name, size, enrichment score (ES), 
normalised enrichment score (NES), p value, False discovery rate (FDR) q value, and leading edge analysis. 
Ferrari et al. Supplementary Information. Supplementary Table 1 (continued). 
Antibody Company Cat. No Clonal 
Dilution 
IF WB IHC IP FACS 
Tissue 
IF 
Alexa Fluor® 488 Donkey Anti-Mouse IgG (H+L) Antibody invitrogen A21202 polyclonal 1:300           
Alexa Fluor® 488 Goat Anti-Rabbit IgG (H+L) Antibody invitrogen A11008 polyclonal 1:300           
Alexa Fluor® 555 Donkey Anti-Mouse IgG (H+L) invitrogen A31570 polyclonal 1:300           
Alexa Fluor® 555 Goat Anti-Rabbit IgG (H+L) Antibody invitrogen A21428 polyclonal 1:300           
CD140a (PDGFRa) Antibody - PE anti-mouse  BioLegend 135905 polyclonal         1:100   
CD31  Clone  MEC 13.3  (RUO), 25ug - APC Rat Anti-Mouse  BD Pharmingen™ 561814 monoclonal         1:200   
CD326 (Ep-CAM) Antibody, 25ug - PE/Cy7 anti-mouse BioLegend 118215 monoclonal          1:100   
CD45  Clone  30-F11  (RUO), 0.1mg - FITC Rat Anti-Mouse  BD Pharmingen™ 553079 monoclonal         1:200   
DAPI     n/a 1:500           
Dkk1 Proteintech 21112-1-AP polyclonal           1:200 
DKK2 antibody - aminoterminal end Abcam ab38594 polyclonal   1:1000         
DKK3 (human) Sigma/Atlas HPA011868 polyclonal     1:100       
DKK3 (human) R&D AF1118 polyclonal   1:1000         
Dkk3 (mouse) Affinity Purified Polyclonal Ab, 100ug R&D AF948 polyclonal   1:1000         
DKK-3 H-130 Santa Cruz sc-25518 polyclonal     1:100       
Fibroblast activation protein, alpha antibody Abcam ab28244 polyclonal 1:100 1:1000         
Fibronectin Dako  A0245 polyclonal     1:2000       
FLAG M2  Cell Signalling 14793 monoclonal       1:50     
FLAG M2  Sigma F1804 monoclonal    1:1000         
GAPDH (14C10) Rabbit mAB cell signaling 3683 monoclonal   1:2000         
HSF1 Cell Signalling 4356S polyclonal   1:1000         
HSF1 Ab-1 (Clone 4B4) Thermo Scientific RT-405-P1 polyclonal 1:100 1:1000         
Kremen-1 (human) Antibody, 25ug R&D MAB2127-SP monoclonal   1:1000   1:50     
Kremen-1 (mouse) Antibody R&D AF1647-SP polyclonal   1:1000         
Laminin Dako  S0809 polyclonal     1:100        
LRP6 (C47E12) Rabbit mAb Cell Signalling #3395 monoclonal   1:1000         
Non-phospho (Active) β-Catenin (Ser33/37/Thr41)  Cell Signaling  #8814 monoclonal 1:100 1:1000 1:100       
Phalloidin-FITC Sigma P1951 n/a 1:500           
Phalloidin-TRITC Sigma P1951 n/a 1:500           
phospho-Myosin Light Chain 2 (Thr18/Ser19) cell signaling 3674 polyclonal   1:1000         
Phospho-Src Family Kinases (Y416) Cell Signaling #2101 polyclonal   1:1000         
phospho-YAP (ser127) Cell Signaling #4911 polyclonal   1:1000         
Polyclonal Goat anti-Mouse immunoglobulins HRP DAKO P044701-2 polyclonal   1:5000         
Polyclonal Goat anti-Rabbit immunoglobulins HRP DAKO P044801-2 polyclonal   1:5000         
Polyclonal Rabbit anti-Goat Immunoglobulins HRP Dako  P0449 polyclonal   1:5000         
S100A4 (FSP1) Abcam ab27957 polyclonal 1:100 1:1000       1:200 
ß-catenin (E-5) Santa Cruz sc-7963 monoclonal 1:100 1:1000 1:100     1:200 
TAZ (V386)  Cell Signaling  #4883 polyclonal 1:100 1:1000         
YAP Santa cruz sc-101199 monoclonal  1:200 1:2000       1:200 
αSMA Sigma A2547 monoclonal  1:500 1:5000       1:200 
αSMA Dako  M0851 monoclonal     1:200       
β-Tubulin I  Sigma T7816 monoclonal   1:5000         
Supplementary Table 2. Antibodies. Name, company, catalogue number and working dilutions of all the antibodies used in the study. 
Ferrari et al. Supplementary Information. Supplementary Table 2. 
NAME target sequence 
sh HuDKK3_1-TRCN0000033398 human shDKK3 CCGGGACACGAAGGTTGGAAATAATCTCGAGATTATTTCCAACCTTCGTGTCTTTTTG 
sh HuDKK3_2-TRCN0000033396 human shDKK3 CCGGCCCAGCATGTACTGCCAGTTTCTCGAGAAACTGGCAGTACATGCTGGGTTTTTG 
sh HuDKK3_3-TRCN0000033395 human shDKK3 CCGGGCAAACTTACCTCCCAGCTATCTCGAGATAGCTGGGAGGTAAGTTTGCTTTTTG 
sh HuDKK3_4-TRCN0000033394 human shDKK3 CCGGGCACCGAGAAATTCACAAGATCTCGAGATCTTGTGAATTTCTCGGTGCTTTTTG 
Supplementary Table 3. shRNAs. :Gene, name and sequences of the single shRNAs used in the study 
Ferrari et al. Supplementary Information. Supplementary Table 3. 
REF NAME Individual siRNA Sequence 
MU-060631-00-0002 siGENOME Mouse DKK3 D-060631-01, Dkk3 UCAAUGAGAUGUUUCGAGA 
    D-060631-02, Dkk3 AAGCUUACCUCCCAACUAU 
    D-060631-03, Dkk3 AGACCAGGGUGGGAAAUAA 
    D-060631-04, Dkk3 GAGGAGCCAUGAAUGUAUC 
MU-018352-01-0005 siGENOME Human DKK3 D-018352-01, Dkk3 AAACUUACCUCCCAGCUAU 
    D-018352-02, Dkk3 CCGAGAAAUUCACAAGAUA 
    D-018352-03, Dkk3 GGACACGCAGCACAAAUUG 
    D-018352-04, Dkk3 UCAAUGAGAUGUUCCGCGA 
MU-060757-01-005 siGENOME Mouse DKK2 D-060757-01, Dkk2 GCAAACCAGUGCUCCAUCA 
    D-060757-02, Dkk2 CAACCGAUCUGCAGGCAUG 
    D-060757-03, Dkk2 GACCUGGGAUGGCAGAAUC 
    D-060757-04, Dkk2 CCUGGUACCGCUGCAAUA 
M-003846-01-0005 siGENOME Human Kremen1 D-003846-01, Kremen1 GAGCACAACUAUUGCAGAA 
    D-003846-02, Kremen1 GAACGAGACUUUCCAGCAU 
    D-003846-03, Kremen1 UCACAGCCAUUGUAGCAAA 
    D-003846-04, Kremen1 CAACGUCUCUCUGGACUUC 
M-046771-01-0005 
siGENOME Mouse Kremen1 
(SMART pool) D-046771-01, Kremen1 AGUCAGAGAUUCAAGUUUG 
    D-046771-02, Kremen1 UCACAGCAGUUGUCGCAAA 
    D-046771-03, Kremen1 GGAACAAUCCUGACUACUG 
    D-046771-04, Kremen1 CCAGGGAUUGCUGUGUUG 
M-049736-00-0005 
siGENOME Mouse Kremen2 
(SMARTpool) D-049736-01, Kremen2 GCGCAUAACUUCUGUAGGA 
    D-049736-02, Kremen2 GAACGGCGCUGACUACCGA 
    D-049736-03, Kremen2 GCACAGGCUUCGAUAGGUG 
    D-049736-04, Kremen2 GCUGGACGCCCUUGUCUUU 
MU-041057-01-0002 siGENOME Mouse Wwtr1 D-041057-01, Wwtr1 GGCCAGAGAUACUUCCUUA 
    D-041057-02, Wwtr1 CCACAGGGCUCAUGAGUGU 
    D-041057-03, Wwtr1 GGAUUAGGAUGCGUCAAGA 
    D-041057-04, Wwtr1 CGAGAUGGAUACAGGUGAA 
MU-046247-01-0002 siGENOME Mouse Yap1 D-046247-01, Yap1 GGAGAAGUUUACUACAUAA 
    D-046247-02, Yap1 CCACCAAGCUAGAUAAAGA 
    D-046247-03, Yap1 GAGAUGCAAUGAACAUAGA 
    D-046247-04, Yap1 CAAUAGUUCCGAUCCCUUU 
M-040650-01-005 siGENOME Mouse LRP5 D-040650-01, Lrp5 GCACAAAGGCCACACUAUA 
    D-040650-02, Lrp5 GGACUGACCUGGACACCAA 
    D-040650-03, Lrp5 UCAAAGCCAUCAACUAUGA 
    D-040650-04, Lrp5 CCAACGACCUCACCAUUGA 
M-040651-01-0005 siGENOME Mouse LRP6  D-040651-01, LRP6 GGACAGACCUGGACACUAA 
    D-040651-02, LRP6 GGAAAGACCUGCAAAGAUG 
    D-040651-03, LRP6 UCACAUAUCUGCCUUGUAA 
    D-040651-04, LRP6 GGACGGAUCUGACCGAGUA 
M-040628-00-0005 siGENOME Mouse Ctnnb1 D-040628-01, Ctnnb1 GAUCUUAGCUUAUGGCAAU 
    D-040628-02, Ctnnb1 GCAAGUAGCUGAUAUUGAC 
    D-040628-03, Ctnnb1 CAGUGGCCUGGUUUGAUA 
    D-040628-04, Ctnnb1 GAACGCAGCAGCAGUUUGU 
M-040660-01-0005 siGENOME Mouse Hsf1 D-M-040660-01, Hsf1 GCUAAGUGAUCACCUGGAU 
    D-M-040660-02, Hsf1 CAAGUAUGGUCGACAGUAC 
    D-M-040660-02, Hsf1 AGAACGAGCUAAGUGAUCA 
    D-M-040660-02, Hsf1 UGCGGCAGCUCAACAUGUA 
M-063467-01-0005 siGENOME Mouse Lats1 D-063467-01, Lats1 GCAGAGUACUAGCAAAUUU 
    D-063467-02, Lats1 GCAGCUGCCAGGCCUAUUA 
    D-063467-03, Lats1 GGAACAGUCAUAACAUGGA 
    D-063467-04, Lats1 GAAACGUUCCUCAGUCGAU 
M-044602-01-0005 siGENOME Mouse Lats2 D-044602-01, Lats2 GCGGCAAUAUUUAGACUUU 
    D-044602-02, Lats2 GAAAUAGCCGGCAGCGAUU 
    D-044602-03, Lats2 GGGCCAAGACGGACAAGUC 
    D-044602-04, Lats2 UCAGGGAAAUCCGAUAUUC 
Supplementary Table 4. siRNas.: Name, catalogue number, and sequence of the single siRNAs used in the study. 
Ferrari et al. Supplementary Information. Supplementary Table 4. 
qPCR Primers 
Primer name Sequence 
hRPLP1_F AGCCTCATCTGCAATGTAGGG 
hRPLP1_R TCAGACTCCTCGGATTCTTCTTT 
mRplp1-F ACCGTGCCGGCAGTCTACAG 
mRplp1-r ATGTTGACATTGGCCAGAGCCTTG 
hGAPDH_F GGCAAATTCCATGGCACCG 
hGAPDH_R GCATCGCCCCACTTGATTTT 
mGapdh_F GTGCAGTGCCAGCCTCGTCC 
mGapdh_R GCCACTGCAAATGGCAGCCC 
mDkk3-TRC_F CTCGGGGGTATTTTGCTGTGT 
mDkk3-TRC_R TCCTCCTGAGGGTAGTTGAGA 
hDKK3a_F AGGACACGCAGCACAAATTG 
hDKK3a_R CCAGTCTGGTTGTTGGTTATCTT 
mHsf1_F4 AACGTCCCGGCCTTCCTAA 
mHsf1_R4 AGATGAGCGCGTCTGTGTC 
mHsf1_F1 TTGACTCCATCCTTCGAGAGAG 
mHsf1_R1 GTCAGGCAGGCTCATGTCG 
mKrt18_F TCAAGATCATCGAAGACCTGAGG 
mKrt18_R GCGCATGGCTAGTTCTGTC 
mPdgfra_F AGAGTTACACGTTTGAGCTGTC 
mPdgfra_R GTCCCTCCACGGTACTCCT 
mPtprc_F ACGCTGGTGCTCTATGCAAG 
mPtprc_R TCAGTTGCTGCCCATTCATCA 
mPecam1_F GTTTTCGCTACATGACTGCACA 
mPecam1_R AGGTTGTCCAACTGACATCTTTC 
mFap_F GTCACCTGATCGGCAATTTGT 
mFap_R CCCCATTCTGAAGGTCGTAGAT 
mFn1_f GCTCAGCAAATCGTGCAGC 
mFn1_r CTAGGTAGGTCCGTTCCCACT 
mDkk3-promoter_F AGGATGGACACCAACAGTCC 
mDkk3-promoter_R TCAGGTACACAGCCCATTTTC 
mDkk3-Enhancer_F CCAGGGTTTGTTCTCAAGGA 
mDkk3-Enhancer_R ACTGTGTGGGCCTAGAATGG 
mRilpl_F AGAACCTTCTGGAAGCACGA 
mRilpl_R GCTTCTGGCAACAAGAGGAG 
Supplementary Table 5. Primers. Names and sequences (forward and reverse) of the paired oligos used in this study for qRT-PCR. The 
name contains the target gene; h stands for human, m for murine; F for forward and R for Reverse). 
Ferrari et al. Supplementary Information. Supplementary Table 5. 
Term Overlap P-value 
Adjusted 
P-value 
Old P-
value 
Old 
Adjusted 
P-value 
Z-score 
Combine
d Score 
Genes 
pou4f1_20376082_fetal_liver_lof_mouse_gpl1261_gds4042_dow
n 1/144 0.0072 0.038 0.004257 0.022424 -2.61051 12.87939 DKK3 
nrf1_22586274_liver_lof_mouse_gpl4134_gse35124_down 1/109 0.00545 0.038 0.003229 0.022424 -2.21245 11.53159 DKK3 
hnf1b_16297991_hek293_embryonic_gof_mouse_gpl96_gds1499
_up 1/170 0.0085 0.038 0.00502 0.022424 -1.9209 9.158274 DKK3 
creb1_22108299_lung_lof_mouse_gpl1261_gds3660_up 1/200 0.01 0.038 0.005901 0.022424 -1.77125 8.156887 DKK3 
tcof1_15522210_neuroblastoma_lof_mouse_gpl339_gds998_dow
n 1/183 0.00915 0.038 0.005402 0.022424 -1.72895 8.115714 DKK3 
gata4_16914500_e9dot5_atrioventricular_canal_lof_mouse_gpl1
261_gds3663_up 1/354 0.0177 0.05605 0.010422 0.033004 -1.61784 6.526694 DKK3 
smarcc2_00000000_e12dot5_embryonic_cortex_lof_mouse_gpl6
887_gse45629_up 1/879 0.04395 0.071031 0.025835 0.04175 -1.83663 5.738911 DKK3 
pou5f1_20526341_human_embryonic_stem_cells_hesc_lof_hum
an_gpl6947_gse21135_up 1/612 0.0306 0.071031 0.017997 0.04175 -1.30692 4.556911 DKK3 
glis2_17618285_kidney_lof_mouse_gpl2897_gds2817_up 1/913 0.04565 0.071031 0.026833 0.04175 -1.40414 4.334235 DKK3 
tcof1_15522210_neuroblastoma_gof_mouse_gpl339_gds998_do
wn 1/742 0.0371 0.071031 0.021813 0.04175 -1.21492 4.002126 DKK3 
zfpm2_19411579_heart_lof_mouse_gpl1261_gds3659_up 1/882 0.0441 0.071031 0.025923 0.04175 -1.28042 3.996579 DKK3 
ccnd1_18413728_imr_neuroblastoma_lof_human_gpl570_gse886
6_up 1/809 0.04045 0.071031 0.02378 0.04175 -1.21973 3.912517 DKK3 
creb1_22108299_heart_left_ventricle_lof_mouse_gpl1261_gds36
60_up 1/972 0.0486 0.071031 0.028566 0.04175 -1.08551 3.282717 DKK3 
hsf1_17216044_hela_lof_human_gpl571_gds1733_up 1/2136 0.1068 0.144943 0.062739 0.085145 -1.28888 2.882952 DKK3 
bmi1_17452456_medulloblastoma_lof_human_gpl570_gds2724_
up 1/7126 0.3563 0.396414 0.209236 0.232791 -1.24068 1.280359 DKK3 
pcgf2_17452456_medulloblastoma_lof_human_gpl570_gds2724_
up 1/7511 0.37555 0.396414 0.220539 0.232791 -1.26344 1.237366 DKK3 
ets_00000000_2008_ovarian_cancer_cells_gof_human_gpl6244_
gse21129_up 1/4717 0.23585 0.298743 0.138512 0.175449 -0.79622 1.150189 DKK3 
rnf2_20805357_u2os_osteosarcoma_lof_human_gpl570_gse2303
5_up 1/5469 0.27345 0.324722 0.16059 0.1907 -0.83405 1.081454 DKK3 
sin3a_22783022_mcf7_lof_human_gpl570_gds4388_up 1/4976 1 1 1 1 -1.11414 -9.5E-12 DKK3 
Supplementary Table 6. TF-LOF Expression from GEO dataset for DKK3 from Enrich. Name, description and statistics of TFs that affect 
DKK3 expression after loss-of-function. 
Ferrari et al. Supplementary Information. Supplementary Table 6. 
